 
 
 
CLINICAL STUDY PROTOCOL  
 
 
Protocol Number:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
 
  
Date of Protocol:   
Version # [ADDRESS_436292]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 
   
   INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
  
Date of Protocol:   
Version# [ADDRESS_436293]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by [CONTACT_22138], instructions, and restrictions contained in the attached protocol. 
 
Additionally, I will not initiate this study without approval of the appropriate Institutional 
Review Board (IRB), and I understand that any changes in the protocol must be approved in writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to subjects.  
 
 
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    
   
   
   
CA-ALT -801-01-10 CONFIDENTIAL             Version#: 01  
IND 100174       October 31, 2010  
 
Page 3 of 67 
 Table of Contents  
SYNOPSIS  ........................................................................................................................................ 7 
1. OBJECTIVES  ........................................................................................................................ 12 
1.1 P RIMARY OBJECTIVES  ....................................................................................................... 12 
1.2 S ECONDARY OBJECTIVES  .................................................................................................. 12 
2. BACKGROUND  .................................................................................................................... 12 
2.1 ALT -801  – GENERAL INFORMATION  ................................................................................ 12 
2.2 B LADDER CANCER  ............................................................................................................ 12 
2.3 I MMUNOTHERAPY  ............................................................................................................. 13 
2.4 I NTRATUMORAL TARGETIN G AND P 53 AS A TARGET FOR BIO THERAPY  .............................. 13 
2.5 P53 AS A THERAPEUTIC TA RGET FOR BLADDER CANCER  .................................................... 15 
2.6 IN VITRO CHARACTERIZATION AND  TUMOR EFFICACY STUD IES IN ANIMAL MODELS  .......... 15 
2.7 N ON-CLINICAL TOXICOLOGY  ............................................................................................ 16 
2.7.1 Single-dose toxicity study ......................................................................................... 16 
2.7.2 Multi-dose toxicity study .......................................................................................... 17 
2.8 P HARMACOKINETICS  ......................................................................................................... 17 
2.8.1 Non-clinical pharmacokinetics ................................................................................ 17 
2.8.2 Clinical pharmacokinetics ....................................................................................... 18 
2.9 H UMAN EXPERIENCE  ......................................................................................................... 18 
2.9.1 Pharmacodynamics .................................................................................................. 18 
2.9.2 Tumor assessment  .................................................................................................... 19 
2.9.3 Safety resu lts ............................................................................................................ 20 
2.9.4 Repeat treatment  ...................................................................................................... 21 
3. RATIONAL FOR THE CURRENT STUDY  ...................................................................... 21 
4. OVERALL STUDY DESIGN  ............................................................................................... 23 
5. STUDY POPULATION ........................................................................................................ 24 
5.1 
INCLUSION CRITERIA  ......................................................................................................... 24 
5.2 E XCLUSION CRITERIA  ........................................................................................................ 25 
5.3 I NCLUSION OF WOMEN AND MINORITIES ............................................................................ 25 
6. STUDY DESIGN .................................................................................................................... 26 
6.1 S TUDY FLOW DIAGRAM  ..................................................................................................... 26 
6.2 S CREENING AND ENROLLM ENT ......................................................................................... 26 
6.2.1 Preliminary screening  .............................................................................................. 26 
6.2.2 Comprehensive screening & enrollment  .................................................................. 27 
6.3 S TUDY TREATMENT ........................................................................................................... 27 
6.3.1 Treatment setting  ..................................................................................................... 27 
6.3.2 Treatment regimen  ................................................................................................... 27 
TREATMENT DAY ...................................................................................................................... 27 
6.3.3 Pre-therapy interventions ........................................................................................ 28 
[IP_ADDRESS]. Pre-medication and IV fluids for ALT-801 ..................................................... 28 
CA-ALT -801-01-10 CONFIDENTIAL             Version#: 01  
IND 100174       October 31, 2010  
 
Page 4 of 67 
 [IP_ADDRESS]. Pre-medication and  IV fluids for cisplatin  ....................................................... 28 
[IP_ADDRESS]. Pre-medication and IV fluids for gemcitabine ................................................. 28 
6.3.4 Study drug preparation and administration  ............................................................ 29 
[IP_ADDRESS]. ALT -801 .......................................................................................................... 29 
[IP_ADDRESS]. Cisplatin  ........................................................................................................... 29 
[IP_ADDRESS]. Gemci tabine ..................................................................................................... 29 
6.4 D URATION OF PATIENT P ARTICIPATION  ............................................................................. 29 
6.5 D OSE ESCALATION  ............................................................................................................ 29 
6.6 E XPANSION AT MTD  ........................................................................................................ 29 
6.7 S TOPPI[INVESTIGATOR_16442]  ............................................................................................................... 30 
6.8 P ATIENT MONITORING , ANTI -TUMOR RESPONSE EVALU ATION , SURVIVAL ASSESSM ENT .... 30 
6.9 T REATMENT DISCONTINUATION  ........................................................................................ 31 
6.9.1 Treatment discontinuation events ............................................................................ 31 
[IP_ADDRESS]. Any serious adverse event ............................................................................... 31 
[IP_ADDRESS]. Cardiac Arrhythmia, Ischemia/Infarction  ........................................................ 31 
[IP_ADDRESS]. Hypotension ..................................................................................................... 31 [IP_ADDRESS]. Kidney dysfunction .......................................................................................... 31 [IP_ADDRESS]. Blood count ...................................................................................................... 32 [IP_ADDRESS]. Allergic reactions and cytokine release syndrome/acute infusion reaction  ..... 32 
[IP_ADDRESS]. Lymphopenia and Neutropenia ........................................................................ 32 [IP_ADDRESS]. Other grade 3/4 adverse events  ........................................................................ 32 
[IP_ADDRESS]. Other events  ..................................................................................................... 32 
[IP_ADDRESS]. Oncological surgeries post study drug treatment ............................................. 33 
6.9.2 Follow-ups after treatment discontinuation............................................................. 33 
[IP_ADDRESS]. Discontinuation due to SAEs or on-going study drug related AEs ................. 33 [IP_ADDRESS]. Discontinuation due to any other reasons ........................................................ [ADDRESS_436294] COURSES OF STUDY TREATMENT  ....................................................... 33 
6.10.1 Q
ualification  ............................................................................................................ 33 
6.10.2 Treatment schedule and procedures ........................................................................ 33 
6.11 G ENERAL SUPPORTIVE CA RE GUIDELINES AND DRUG INTERACTION  .................................. 33 
6.11.1 ALT-801 ................................................................................................................... 33 
[IP_ADDRESS]. Hypotension and capi[INVESTIGATOR_12737] ....................................................... 34 [IP_ADDRESS]. Pulmonary dysfunction .................................................................................... 34 [IP_ADDRESS]. Impaired kidney and liver functions ................................................................ 34 [IP_ADDRESS]. Infection  ........................................................................................................... 34 
[IP_ADDRESS]. Fever and chills ................................................................................................ 35 [IP_ADDRESS]. Gastritis  ............................................................................................................ 35 
[IP_ADDRESS]. Diarrhea, nausea and vomiting ........................................................................ 35 [IP_ADDRESS]. Pruritus and dermatitis  ..................................................................................... 35 
[IP_ADDRESS]. Acidosis............................................................................................................ 35 [IP_ADDRESS]. Life-threatening toxicities  ................................................................................ 35 
[IP_ADDRESS]. Other supportive care ....................................................................................... 35 [IP_ADDRESS]. Drug interaction  ............................................................................................... 35 
6.11.2 Cisplatin  ................................................................................................................... 36 
6.11.3 Gemcitabine ............................................................................................................. 36 
CA-ALT -801-01-10 CONFIDENTIAL             Version#: 01  
IND 100174       October 31, 2010  
 
Page 5 of 67 
 7. STUDY DRUG: AVAILABILITY, ACCOUNTABILITY, PACKAGING & 
LABELING  .................................................................................................................................... 37 
7.1 ALT -801 .......................................................................................................................... 37 
7.1.1 Availability  ............................................................................................................... 37 
7.1.2 Accountability .......................................................................................................... 37 
7.1.3 Packaging ................................................................................................................ 37 
7.1.4 Labeling ................................................................................................................... 37 
7.2 C ISPLATIN AND GEMCITABINE  .......................................................................................... 37 
8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS ........................................ 38 
8.1 S TUDY CALENDAR  ............................................................................................................ 38 
8.2 P ROCEDURES AND TESTS  ................................................................................................... 39 
8.2.1 HLA -A2 typi[INVESTIGATOR_007] ......................................................................................................... 39 
8.2.2 Presentation of HLA-A*0201/p53 aa264-[ADDRESS_436295]  .......................................................................................................... 39 
8.2.5 Physical examination ............................................................................................... 39 
8.2.6 Vital signs & body weight ........................................................................................ 39 
8.2.7 Cardiac assessment .................................................................................................. 39 
8.2.8 Blood tests ................................................................................................................ 39 
8.2.9 Urinalysis  ................................................................................................................. 40 
8.2.10 Pulmonary functions ................................................................................................ 40 
8.2.11 Adverse event assessment  ........................................................................................ 40 
8.2.12 Tumor assessment  .................................................................................................... 40 
8.2.13 Survival assessment ................................................................................................. 40 
8.2.14 Pharmacokinetic (PK) testing .................................................................................. [ADDRESS_436296] overall response ......................................................................... 44 
9.4 C ONFIRMATORY  ................................................................................................................ 45 
10. STATISTICAL ANALYSIS  ............................................................................................. 45 
10.1 S TUDY OBJECTIVES  ........................................................................................................... 45 
10.2 S AMPLE SIZE  ..................................................................................................................... 45 
CA-ALT -801-01-10 CONFIDENTIAL             Version#: [ADDRESS_436297] ING, REPORTING AND COMMUNICATION  .................................. 47 
11.2 A DVERSE EVENT TERMINO LOGY AND DEFINITIONS  ........................................................... 48 
11.3 A DVERSE EVENT REPORTING PROCEDURES  ...................................................................... 49 
11.4 A DVERSE EVENT EXPEDITED REPORTING GUIDELINES  ..................................................... 49 
11.5 S UBMISSION OF SERIOUS  ADVERSE EVENT REPOR TING  ...................................................... 49 
11.6 D ATA REPORTING FORMS  ................................................................................................. 50 
11.7 R EPORT /DATA SUBMISSION ADDRE SS & CONTACT  ........................................................... 50 
11.8 P ATIENT RECORDS , QUALITY ASSURANCE , RECORDS RETENTION  ...................................... 51 
11.9 M ETHOD OF REVIEW  ......................................................................................................... 51 
11.10 S PECIAL REGULATORY CO NSIDERATIONS  ...................................................................... 51 
11.10.1 HIPAA  .................................................................................................................. 51 
11.10.2 Protocol amendments, informed consent, and IRB approval .............................. 52 
12. CONFIDENTIALITY  ....................................................................................................... 52 
13. ETHICAL STANDARDS & INVESTIGATOR OBLIGATIONS  ................................ [ADDRESS_436298] OF EXPECTED ADVERSE EVENTS  .................................................................. 52 
15. CTCAE ................................................................................................................................ 55 
REFERENCES  ............................................................................................................................... 56 
APPENDIX A: PERFORMANCE STATUS CRITERIA.......................................................... 59 
APPENDIX B: NEW YORK  HEART ASSOCIATION CLASSIFICATION ......................... 59 
APPENDIX C: ETHICAL STANDARDS  ................................................................................... 60 
APPENDIX D: INV ESTIGATOR OBLIGATION S .................................................................. 61 
APPENDIX E: CONTACT [CONTACT_351110] - ALTOR  ............................................................................... 65 
APPENDIX F: CONTACT [CONTACT_351110] – DATA SAFETY MONITORING BOARD (DSM B) ...... 66 
APPENDIX G: CONTACT [CONTACT_351110] - LABORATORIES  ............................................................. 66 
APPENDIX H: APPROVAL  PAGE  ............................................................................................ 67 
CA-ALT -801-01-10 CONFIDENTIAL             Version#: 01  
IND 100174       October 31, 2010  
 
Page 7 of 67 SYNOPSIS  
Sponsor:  Altor  Bioscience Corporation 
Protocol#: CA-ALT -801-01-10 
Study Drug Name:  [CONTACT_351126]:  ALT -801 (c264scTCR- IL2), recombinant humanized, soluble single -chain 
TCR -cytokine fusion protein; Cisplatin; Gemcitabine.  
Study Type:  Interventional 
Study Phase:  Ib/II 
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination with Cisplatin and 
gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer  
Objectives:    To determine the safety and tolerability of the novel combination of addition 
of ALT -801 (c264scTCR -IL2) to the doublet of cisplatin and gemcitabine in 
patients with muscle invasive or metastatic urothelial cancer of bladder, renal pelvis, ureters and urethra.   
To estimate the anti- tumor activity of this combination of ALT -801, 
cisplatin and gemcitabine by [CONTACT_351111]-tumor response; 
progression free survival (assessed through end of study); and overall survival (assessed through end of study) in treated patients.  
To characterize the pharmacokinetic profile of ALT -801 in combination 
with cisplatin and gemcitabine in treated patients.  
Study Design:  This is a Phase Ib/II, open- label, multi- center, competitive enrollment and 
dose-escalation study of ALT-[ADDRESS_436299] muscle invasive or metastatic urothelial cancer of bladder, renal pelvis, ureters and urethra, who are HLA-A2 positive by [CONTACT_351112][INVESTIGATOR_351095] -A*0201/p53 aa264-272 complex.  The study will be conducted in 
conformity with Good Clinical Practice (GCP).  
The study includes a dose escalation phase to determine the maximum 
tolerated dose (MTD) of ALT-801 in combination with cisplatin and gemcitabine and a two -stage expansion phase at t he MTD.  The dose 
escalation in this study is conducted using a (3+3) dose escalation design, and the two-stage expansion phase at the MTD using a modified Simon two-stage design (1, 2).  In the dose escalation phase of this study, there are three dose levels of ALT-801 (0.04 mg/kg, 0.06 mg/kg and 0.08 mg/kg, in addition to two de-escalation dose levels).  The doses of cisplatin (75 mg/m
2/dose, day 1) and gemcitabine (1000 mg/m2/dose, day 1 & 8) will be 
fixed across all ALT -[ADDRESS_436300] and 
the principal investigators will meet to discuss whether to amend the protocol to expand the dose escalation phase to include additional ALT-801 dose levels.  
CA-ALT -801-01-10 CONFIDENTIAL             Version#: 01  
IND 100174       October 31, 2010  
 
Page 8 of 67 Treatments:  The planned on-stud y treatment duration will be for 3 courses.  Each course 
consists of cisplatin (Day #1), gemcitabine (Day #1), ALT -801 (Day #3 & 
Day #5), gemcitabine (Day #8), ALT -801 (Day #8 & Day #10), and a rest 
period (Days #11- 21).  Delays or modifications are addressed in the 
protocol. This is illustrated in this schema: 
 
 Course1  Course [ADDRESS_436301] course, subjects will need to 
meet the continuation criteria. Enrolled patients will receive the study treatment at qualified cancer treatment centers with adequate di agnostic and 
treatment facilities to provide appropriate management of therapy and complications. The ALT -801, the cisplatin and gemcitabine will be 
administered by [CONTACT_351113] a central or peripheral vein under the supervision of a qualified physician experienced in the use of anti -cancer 
agents including aldesleukin (Proleukin
), cisplatin and gemcitabine . 
This is the schema for the dose levels during the dose -escalation phase of the 
study.  The -1 and - 2 dose levels of ALT -801 are included in case of DLT 
events in the initial dose level.  
Cohort  ALT- 801 Dose (mg/kg)  Cisplatin  (mg/m2) Gemcitabine (mg/m2) 
-2 0.01 75 1000  
-1 0.02 75 1000  
1 (initial)  0.04 75 1000  
2 0.06 75 1000  
3 0.08 75 1000  
Dose Escalation:  In this phase of the study, a minimum of 3 patients will be enrolled at each dose level.  All patients will be monitored for Dose Limiting Toxicity (DLT) for 8 weeks from the initial dose.  If 0/[ADDRESS_436302] a DLT that is drug -related, that dose level will 
be designated as exceeding the maximum tolerated dose. If there are 3 patients in the dose level below this level, then additional patients (up to 6 total) will be enrolled at that dose level. When there is a dose level with 0 or 1 out of 6 patients with DLT, which is either the maximum planned dose level (level 3) or which is one level below a dose that was not tolerated, the dose that is the maximum tolerated dose will be considered defined. Further 
CA-ALT -801-01-10 CONFIDENTIAL             Version#: 01  
IND 100174       October 31, 2010  
 
Page 9 of 67 changes in the treatment plan may be considered by [CONTACT_351114]. 
If more than two of six patients experience a DLT at the initial dose level 
(level 1), then the sponsor, the Data Safety Monitoring Board and the principal investigators will meet to determine how to adjust downward the dose level of cisplatin, gemcitabine, and/or the study drug, or continue with the (-1) and (-2) cohorts, and to determine how to proceed with the study.  
A DLT is any toxicity that results in study treatment discontinuation and 
includes definitions below.  Study treatment discontinuation due to adverse 
events experienced prior to study drug administration, disease progression or patie nt’s decision to withdraw from the study treatment without occurrence 
of any study treatment discontinuation event will not necessarily define a DLT event.  Study treatment discontinuation events are defined in the protocol.  
Dose Expansion : T
 he two -stage expansion phase at the MTD will be conducted using a 
modified Simon two -stage design (1, 2) .  Both objective response (OR) 
(defined as complete response (CR) + partial response (PR)) and clinical benefit (CB) (defined as CR, PR + stable disease (SD)) will be evaluated and common set t hresholds of lack of efficacy (OR rate (ORR) = 40%; CB rate 
(CBR) = 78%) and an efficacy level of interest (ORR = 60%; CBR = 92%) will be selected.  The sample size was driven by [CONTACT_351115].      
Stoppi[INVESTIGATOR_007] R ule: The patient enrollment will be temporarily suspended based on occurrence of any the following, and the sponsor, the Data Safety Monitoring Board and principal investigators will meet to discuss how to proceed with future patient enrollment in the stud y: 
• If at any time the dose escalation phase of the study, more than one patient in a cohort of three, or two of six patients experience any DLT; 
• If at any time during the expansion phase of the study, more than 33% the patients experience any drug related DLT.  
Evaluations: Patients will be evaluated for clinical toxicities during the treatment.  Patients’ blood samples will be collected to assess the pharmacokinetic profile and immunogenicity of the study drug. The anti -tumor response will 
be evaluated for up to [ADDRESS_436303] one dose of the study drug ALT -
801 will be included in the anti -tumor response evaluation.  Between each 
cohort and at the end of the study, all clini cal and safety data will be 
analyzed for all patients enrolled in the study for dose- response effects.  
Population:  Patients of 18 years of age and above who are candidates for systemic cisplatin and gemcitabine for the treatment of muscle invasive or metas tatic 
urothelial cancer of bladder, renal pelvis, ureters, and urethra, who are HLA -
A2 positive by [CONTACT_351112][INVESTIGATOR_351096] -A*0201/p53 aa264 -272 complexes (as detected by [CONTACT_3211] -provided 
test on tumor biopsy or surgically removed tumor samples) may be selected 
CA-ALT -801-01-10 CONFIDENTIAL             Version#: [ADDRESS_436304] an Eastern Cooperative Oncology Group (ECOG) performance status of [ADDRESS_436305] 12 weeks.  
Sample Size:  A total of up to 30 assessable  patients will be accrued to the initial dose 
escalation phase of the study (Phase Ib); the estimated number is 15.  Up to an additional 40 assessa ble patients will be enrolled at the expansion phase 
(Stage 1 and 2) of the study (Phase II) .  A total of approximately 58 
assessable patients will be enrolled and complete the study.  Assume a 20% ineligible or non - assessable cases, a total of up 70 patients may be accrued 
to the study. 
Primary  
Endpoints:  
For Stage I only:  (1) To define an MTD of ALT-801 in combination with cisplatin and 
gemcitabine in the treatment of patients with muscle invasive or metastatic urothelial cancer.  
For Stage I & II:  (2) To assess the safety of the combination study treatment in treated 
patients.  
 (3) To assess the objective response rate in treated patients.  
Secondary  
Endpoints:  (1) To assess the progression free survival in treated patients.  
(2) To assess the overall survival in treated patients.  
(3) To evaluate the immugonenicity and pharmacokinetic profile of ALT-
801 in treated patients. 
Pharmacokinetics  
& Biomarkers:  Blood samples for pharmacokinetic analysis of ALT -[ADDRESS_436306] course of study 
treatment. Venous blood will be obtained at Time 0 (before the start of infusion), at 30 min (completion of drug infusion), and 1, 3 and 6 hours from Time 0 for the assessment of ALT -801 serum concentration. Non-
compartmental a nd compartmental analyses will be conducted.  In addition, 
the same blood samples collected for PK analysis will be used to assess the  
serum levels of INF -γ and TNF -α. 
Monitoring Tests:  Urine samples for urinalysis, blood samples for standard chemistry, CBC, 
differential and coagulation will be obtained at screening, on each study drug infusion day, discharge days and follow -up visits.  Blood samples for 
immunogenicity testing, which include assays for anti -ALT -[ADDRESS_436307] ALT -
801 infusion day and at Week 9 from the initial dose of study treatment.  
Anti -tumor  
Response  
Evaluation: The an ti-tumor response will be evaluated at Week 9 and Week 13 from the 
initial dose of study treatment. Objective Response will be evaluated using 
CA-ALT -801-01-10 CONFIDENTIAL             Version#: 01  
IND 100174       October 31, 2010  
 
Page 11 of 67 the new international criteria proposed by [CONTACT_351116] (RECIST) 1. 1.  Baseline evaluations should be 
performed up to [ADDRESS_436308] of the treatment.  
Howe ver, cystoscopic evaluation may be used routinely in this population, in 
addition to radiologic testing.  
Survival  
Assessment:  Progression- free survival and overall survival of all enrolled patients will be 
assessed at 3, 6, 9, 12, 18, 24, 30 and 36 months  from the start of study 
treatment, or through the point designated as the end of the study follow up. 
Adverse Events:  All p
 atients will be monitored and evaluated for clinical toxicities during the 
treatment period and queried at each follow -up visit for Adverse Events 
(AEs).  Patients may volunteer information concerning AEs.  All adverse 
events will be graded by [CONTACT_351117] 4.0 (CTCAE v4.0), and logged in the patient Case Report Form.  The study centers should report all SAEs and all events that trigger patient’s study treatment discontinuation to the sponsor via phone, fax or email (or a combination) up to 1 day after learning of the event.  The sponsor will use the information to manage and coordi nate the dose 
escalation, cohort expansion and patient enrollment.  The sponsor will then inform all of the participating clinical sites of the current dose level and the number of patients to be enrolled at that level, or of any patient enrollment suspens ion via phone, fax or email within a day of its learning of the event.  
The study centers should report the other adverse events to the sponsor following the guidelines defined in the study protocol. All study drug related adverse events (AEs) that are bot h serious and unexpected will be reported 
to the FDA in an expedited manner in accordance with 21 CFR §312.32. 
Statistical Plan:  For  each cohort, all AEs will be tabulated and examined and all safety and 
pharmacokinetic data will be evaluated. For estimation of duration of 
response, the Kaplan- Meier method will be used. P -values of < 0.05 (two-
sided) will be considered to indicate statistical significance.   
CA-ALT -801-01-10 CONFIDENTIAL             Version#: 01  
IND 100174       October 31, 2010  
 
Page 38 of 67 8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS 
8.1 Study calendar  
 
 
1Authorization of the Part I Informed Consent is required before obtaining patients’ blood and tumor samples for HLA -A2 blood typi[INVESTIGATOR_351097] -A*0201/p53 aa264-
[ADDRESS_436309] result on HLA A2 blood typi[INVESTIGATOR_351098]- A*0201/p53 aa264 -272 tumor 
typi[INVESTIGATOR_007] . 3Only patients with positive results on HLA A2 blood typi[INVESTIGATOR_351097]- A*0201/p53 aa264 -[ADDRESS_436310] the possibility of being enrolled in the study.   4Any previous HLA A2 blood typi[INVESTIGATOR_124619], from serological or 
DNA-based typi[INVESTIGATOR_007], and HLA -A*0201/p53 aa264 -272 tumor typi[INVESTIGATOR_351099].   5Screening evaluations are performed < 14 
days, scan/x -ray < 28 days  prior to start of therapy.  If the patient's condition is deteriorating, laboratory evaluations should be repeated within [ADDRESS_436311] is for women wi th childbearing potential only.  7Vital signs (especially blood 
pressure), clinical status and laboratory tests should be reviewed before start of therapy. Vital signs will be evaluated every 2 hours after the drug 
treatment and before discharge, and body weight before the study treatment infusion on study treatment infusion day.  8Patients are closely 
monitored for hypotension, arrhythmia, angina and myocardial infarction. At screening, patients who are ≥ [ADDRESS_436312] (stress thallium, stress MUGA or dobutamine 
echocardiogram) to determine their eligibility for partic ipation in the study. EKG will be performed at start of each treatment cycle.   9Patients who 
have an on -going study drug -related SAE upon study completion or at discontinuation of the study will be contact[CONTACT_33981]/her 
designee every week until the event is resolved or determined to be irreversible. 10Tumor response and progression will be evaluated in this study 
using the new international criteria proposed by [CONTACT_39694] (1.1) Committee.    11Performed at Course #[ADDRESS_436313] blood s amples at Time 0 
(before drug infusion), at 30 min (+/ - 5 min), 1 hour (+/ - 10 min), 3 hour (+/ - 30 min), 6 hour (+/ - 60 min) from Time 0. INF γ and TNFα assays 
are performed using the same samples and at the same schedule as PK .  12Performed at Course #1 only and before dosing.  13Residual samples may 
be used by [CONTACT_351118]. .  14Information about tumor assessment & other therapi[INVESTIGATOR_351100].  TESTS & PROCEDURES  Pre 
Screen  Screen5 TREATMENT PERIOD  
For Course 1 -3 FOLLOW-UP PERIOD   
MONTH      3 6 9 12 18 24  30 36 
WEEK (Course 2 in parenthesis)  
         {Course 3 in brackets}    1 (4){7}  2(5){8}   3 (6)  9 12        
STUDY DAY (Course 2 in parenthesis)  
                   {Course 3 in brackets}    1 
(22) 
{43} 3 
(24) 
{45} 5 
(26) 
{47} 8 
(29) 
{50} 10 
(31) 
{52}  
 
 
 
 
R 
 
E 
 
S 
 
T 
 
 
 
P 
 
E 
 
R 
 
I 
 
O 
 
D 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
           
Informed consent PART I1 X                
Informed consent PART II   X               
HLA A2 Typi[INVESTIGATOR_007]2, 4 X                
HLA -A*0201/p53 aa264 -272 tumor typi[INVESTIGATOR_007]3,  4 X                
Medical history   X               
Serum pregnancy test6  X               
Complete physical exam   X X     X X        
Vital signs, weight, Height7  X X X X X X X X        
Concurrent medication   X X X X X X X X        
Blood tests: CBC with Differential, Blood 
Chemistry & Coagulation   X X X X X X X X        
Urinalysis   X X X X X X X X        
Cardiac functions8  X X X X X X          
Pulmonary functions   X               
Adverse event assessment9  X X X X X X X X        
Tumor assessment10  X      X X        
Survival Assessment14          X X X X X X X 
PK11, INFγ11, TNFα11,13    X             
Immunogenicity tests13    X 12     X         
Cisplatin therapy    X              
Gemcitabine therapy    X   X           
Study drug administration     X X X X          
 
 
 
CLINICAL STUDY PROTOCOL  
 
 
Protocol Number:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
 
  
Date of Protocol:   
Version # 01Version # [ADDRESS_436314]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 
   
   INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
  
Date of Protocol:   
Version# 01  
Version# [ADDRESS_436315]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by [CONTACT_22138], instructions, and restrictions contained in the attached protocol. 
 
Additionally, I will not initiate this study without approval of the appropriate Institutional 
Review Board (IRB), and I understand that any changes in the protocol must be approved in writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to subjects.  
 
 
   
Principal Investigator’s Signature   [CONTACT_351125]’s N ame (Print)    
   
   
   
CA-ALT -801-01-10 CONFIDENTIAL             Version#: 02  
IND 100174             July 8, 2011  
 
Page 3 of 71 
 Table of Contents 
SYNOPSIS  ........................................................................................................................................ 7 
1. OBJECTIVES  ........................................................................................................................ 13 
1.1 P RIMARY OBJECTIVES  ....................................................................................................... 13 
1.2 S ECONDARY OBJECTIVES  .................................................................................................. 13 
2. BACKGROUND  .................................................................................................................... 13 
2.1 ALT -801  – GENERAL INFORMATION  ................................................................................ 13 
2.2 B LADDER CANCER  ............................................................................................................ 13 
2.3 I MMUNOTHERAPY  ............................................................................................................. 14 
2.4 I NTRATUMORAL TARGETIN G AND P 53 AS A TARGET FOR BIO THERAPY  .............................. 14 
2.5 P53 AS A THERAPEUTIC TA RGET FOR BLADDER CANCER  .................................................... 16 
2.6 IN VITRO CHARACTERIZATION AND  TUMOR EFFICACY STUD IES IN ANIMAL MODELS  .......... 16 
2.6.1 Efficacy evaluation of ALT-801 dose regimens in xenograft tumor models ............ 17 
2.6.2 Efficacy of ALT -801 and non- targeted scTCR/IL -[ADDRESS_436316] human p53-negative orthotropic murine bladder 
tumors in immunocompetent mice. .......................................................................................... 19 
2.7 N ON-CLINICAL TOXICOLOGY  ............................................................................................ 20 
2.7.1 Single-dose toxicity study ......................................................................................... 20 
2.7.2 Multi-dose toxicity study .......................................................................................... 20 
2.8 P HARMACOKINETICS  ......................................................................................................... 21 
2.8.1 Non-clinical pharmacokinetics ................................................................................ 21 
2.8.2 Clinical pharmacokinetics ....................................................................................... 21 
2.9 H UMAN EXPERIENCE  ......................................................................................................... 22 
2.9.1 Pharmacodynamics .................................................................................................. 22 
2.9.2 Tumor assessment  .................................................................................................... 22 
2.9.3 Safety results  ............................................................................................................ 23 
2.9.4 Repeat treatment  ...................................................................................................... 24 
3. RAT
IONALE FOR THE CURRENT STUDY ................................................................... 24 
4. OVERALL STUDY DESIGN  ............................................................................................... 25 
5. STUDY POPULATION ........................................................................................................ 27 
5.1 I NCLUSION CRITERIA  ......................................................................................................... 27 
5.2 E XCLUSION CRITERIA  ........................................................................................................ 28 
5.3 I NCLUSION OF WOMEN AND MINORITIES ............................................................................ 28 
6. STUDY DESIGN .................................................................................................................... 29 
6.1 S TUDY FLOW DIAGRAM  ..................................................................................................... 29 
6.2 S CREENING AND ENROLLM ENT ......................................................................................... 29 
6.3 S TUDY TREATMENT ........................................................................................................... 29 
6.3.1 Treatment setting  ..................................................................................................... 30 
6.3.2 Treatment regimen  ................................................................................................... 30 
6.3.3 Pre-therapy interventions ........................................................................................ 31 
CA-ALT -801-01-10 CONFIDENTIAL             Version#: 02  
IND 100174             July 8, 2011  
 
Page 4 of 71 
 [IP_ADDRESS] Pre-medication and IV fluids for ALT-801 ......................................................... 31 
[IP_ADDRESS] Pre-medication and IV fluids for cisplatin ........................................................... 32 
[IP_ADDRESS] Pre-medication and IV fluids for gemcitabine ..................................................... 32 
6.3.4 Study drug preparation and administration ............................................................ 32 
[IP_ADDRESS] ALT -801 .............................................................................................................. 32 
[IP_ADDRESS] Cisplatin  ............................................................................................................... 32 
[IP_ADDRESS] Gemcitabine  ......................................................................................................... 32 
6.4 D URATION OF PATIENT P ARTICIPATION  ............................................................................. 32 
6.5 D OSE ESCALATION  ............................................................................................................ 33 
6.6 E XPANSION AT MTD  ........................................................................................................ 33 
6.7 S TOPPI[INVESTIGATOR_16442]  ............................................................................................................... 34 
6.8 P ATIENT MONITORING , ANTI -TUMOR RES PONSE EVALUATION , SURVIVAL ASSESSMENT  .... 34 
6.8.1 Patient monitoring ................................................................................................... 34 
6.8.2 Anti-tumor response evaluation ............................................................................... 34 
6.8.3 Survival assessment ................................................................................................. 34 
6.9 D OSE LIMITING TOXICITIES  ............................................................................................... 35 
6.10 S TUDY TREATMENT D ISCONTINUATION ............................................................................. 35 
6.10.1 Study treatment discontinuation events ................................................................... 35 
6.10.2 Follow-ups after treatment discontinuation............................................................. 35 
[IP_ADDRESS]. Discontinuation due to SAEs or on-going study drug related AEs ................. 35 
[IP_ADDRESS]. Discontinuation due to any other reasons ........................................................ 35 
6.11 S TUDY TREATMENT ADJUS TMENT  ..................................................................................... 36 
6.11.1 Kidney dysfunction ................................................................................................... 36 
6.11.2 Hematological dysfunction ...................................................................................... 36 
6.11.3 Hypotension ............................................................................................................. 36 
6.11.4 Allergic reactions and cytokine release syndrome/acute infusion reaction ............ [ADDRESS_436317] COURSES OF STUDY TREATMENT  ....................................................... 37 
6.12.1 Qualification  ............................................................................................................ 37 
6.12.2 Treatment schedule and procedures ........................................................................ 37 
6.13 R EPEAT STUDY DRUG TREATMENT  .................................................................................... 37 
6.13.1 Qualification  ............................................................................................................ 37 
6.13.2 Treatment schedule and procedures ........................................................................ 37 
6.14 G ENERAL SUPPORTIVE CA RE GUIDELINES AND DRUG INTERACTION  .................................. 37 
6.14.1 ALT-801 ................................................................................................................... 38 
[IP_ADDRESS]. Hypotension and capi[INVESTIGATOR_12737] ....................................................... 38 [IP_ADDRESS]. Pulmonary dysfunction .................................................................................... 38 [IP_ADDRESS]. Impaired kidney and liver functions ................................................................ 38 [IP_ADDRESS]. Infection  ........................................................................................................... 39 
[IP_ADDRESS]. Fever and chills ................................................................................................ 39 [IP_ADDRESS]. Gastritis  ............................................................................................................ 39 
[IP_ADDRESS]. Diarrhea, nausea and vomiting ........................................................................ 39 [IP_ADDRESS]. Pruritus and dermatitis  ..................................................................................... 39 
[IP_ADDRESS]. Acidosis............................................................................................................ 39 [IP_ADDRESS]. Life-threatening toxicities  ................................................................................ 39 
[IP_ADDRESS]. Other supportive care ....................................................................................... 39 
CA-ALT -801-01-10 CONFIDENTIAL             Version#: 02  
IND 100174             July 8, 2011  
 
Page 5 of 71 
 [IP_ADDRESS]. Drug interaction  ............................................................................................... 39 
6.14.2 Cisplatin  ................................................................................................................... 40 
6.14.3 Gemcitabine ............................................................................................................. 41 
7. STUDY DRUG: AVAILABILITY, ACCOUNTABILITY, PACKAGING & 
LABELING  .................................................................................................................................... 41 
7.1 ALT -801 .......................................................................................................................... 41 
7.1.1 Availability  ............................................................................................................... 41 
7.1.2 Accountability .......................................................................................................... 41 
7.1.3 Packaging ................................................................................................................ 41 
7.1.4 Labeling ................................................................................................................... 41 
7.2 C ISPLATIN AND GEMCITABINE  .......................................................................................... 41 
8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS ........................................ 42 
8.1 S TUDY CALENDAR  ............................................................................................................ 42 
8.2 P ROCEDURE AND TESTS  .................................................................................................... 43 
8.2.1 HLA -A2 typi[INVESTIGATOR_351101] .......................... 43 
8.2.2 Presentation of HLA-A*0201/p53 aa264-[ADDRESS_436318]  .......................................................................................................... 43 
8.2.5 Physical examination ............................................................................................... 43 
8.2.6 Vital signs, body weight & height ............................................................................ 43 
8.2.7 Cardiac assessment .................................................................................................. 43 
8.2.8 Blood tests ................................................................................................................ 44 
8.2.9 Urinalysis  ................................................................................................................. 44 
8.2.10 Pulmonary functions ................................................................................................ 44 
8.2.11 Adverse event assessment  ........................................................................................ 44 
8.2.12 Tumor assessment  .................................................................................................... 44 
8.2.13 Survival assessment ................................................................................................. 44 
8.2.14 Pharmacokinetic (PK) testing .................................................................................. [ADDRESS_436319] overall response ......................................................................... 48 
9.4 C ONFIRMATORY  ................................................................................................................ 49 
CA-ALT -801-01-10 CONFIDENTIAL             Version#: [ADDRESS_436320] ING, REPORTING AND COMMUNICATION  .................................. 51 
11.2 A DVERSE EVENT TERMINO LOGY AND DEFINITIONS  ........................................................... 52 
11.3 A DVERSE EVENT REPORTING PROCEDURES  ...................................................................... 53 
11.4 A DVERSE EVENT EXPEDITED REPORTING GUIDELINES  ..................................................... 53 
11.5 S UBMISSIO N OF SERIOUS ADVERSE EVENT REPORTING  ...................................................... 53 
11.6 D ATA REPORTING FORMS  ................................................................................................. 54 
11.7 R EPORT /DATA SUBMISSION ADDRE SS & CONTACT  ........................................................... 54 
11.8 P ATIENT RECORDS , QUALITY ASSURANCE , RECORDS RETENTION  ...................................... 55 
11.9 M ETHOD OF REVIEW  ......................................................................................................... 55 
11.10 S PECIAL REGULATORY CO NSIDERATIONS  ...................................................................... 55 
11.10.1 HIPAA  .................................................................................................................. 55 
11.10.2 Protocol amendments, informed consent, and IRB approval .............................. 56 
12. CONFIDENTIALITY  ....................................................................................................... 56 
13. ETHICAL STANDARDS & INVESTIGATOR OBLIGATIONS  ................................ [ADDRESS_436321] OF EXPECTED ADVERSE EVENTS  .................................................................. 57 
15. CTCAE ................................................................................................................................ 59 
REF
ERENCES  ............................................................................................................................... 60 
APPENDIX A: PERFORMANCE STATUS CRITERIA.......................................................... 63 
APPENDIX B: NEW YORK  HEART ASSOCIATION CLASSIFICATION ......................... 63 
APPENDIX C: ETHICAL STANDARDS  ................................................................................... 64 
APPENDIX D: INVESTIGATOR OBLIGATIONS  .................................................................. 65 
APPENDIX E: CONTACT [CONTACT_351110] - ALTOR  ............................................................................... 69 
APPENDIX F: CONTACT [CONTACT_351110] – DATA SAFETY MONITORING BOARD (DSM B) ...... 70 
APPENDIX G: CONTACT [CONTACT_351110] - LABORATORIES  ............................................................. 70 
APPENDIX H: APPROVAL  PAGE  ............................................................................................ 71 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 02  
IND 100174                                 July 8, 2011  
Page  7 of 71 SYNOPSIS  
Sponsor:  Altor Bioscience Corporation 
Protocol#: CA-ALT -801-01-10 
Study Drug Name:  [CONTACT_351126]:  ALT -801 (c264scTCR- IL2), recomb inant humanized, soluble single -chain 
TCR -cytokine fusion protein; Cisplatin; Gemcitabine.  
Study Type:  Interventional 
Study Phase:  Ib/II 
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination with Cisplatin and 
gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer  
Objectives:    To determine the safety and tolerability of the novel combination of addition 
of ALT -801 (c264scTCR -IL2) to the doublet of cisplatin and gemcitabine in 
patients with muscle invasive or metastatic urothelial cancer of bladder, renal pelvis, ureters and urethra.   
To estimate the anti- tumor activity of this combination of ALT -801, 
cisplatin and gemcitabine by [CONTACT_351111]- tumor response, 
progression free survival (assessed through end of study), and over all 
survival (assessed through end of study) in treated patients.  
To characterize the immunogenicity and pharmacokinetic profile of ALT -
801 in combination with cisplatin and gemcitabine in treated patients. To assess the relationship between tumor presentation of HLA -A*0201/p53 
aa 264 -272 complex and the safety and clinical benefit of study treatment. 
Study Design:  This is a Phase Ib/II, open- label, multi- center, competitive enrollment and 
dose- escalation study of ALT -[ADDRESS_436322] muscle invasive or metastatic 
urothelial cancer of bladder, renal pelvis, ureters and urethra.  The study will be conducted in conformity with Good Clinical Practice (GCP).  
The study includes a dose esc alation phase to determine the maximum 
tolerated dose (MTD) of ALT -801 in combination with cisplatin and 
gemcitabine and a two -stage expansion phase at the MTD.  The dose 
escalation in this study is conducted using a (3+3) dose escalation design, 
and the t wo-stage expansion phase at the MTD using a modified Simon two -
stage design (1, 2).  In the dose escalation phase of this study, there are five dose levels of ALT -801 (0.04 mg/kg, 0.06 mg/kg and 0.08 mg/kg, 0.10 
mg/kg and 0.12 mg/kg) in addition to two de -escalation dose levels.  The 
doses of cisplatin (70 mg/m
2/dose) and gemcitabine (1000 mg/m2/dose) will 
be fixed across all ALT -[ADDRESS_436323] and the principal investigators will meet to discuss whether to amend the protocol to expand the dose escalation phase to include additional ALT -801 
dose levels.  
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 02  
IND 100174                                 July 8, 2011  
Page  8 of 71 Treatments:  The planned initial on- study treatment will be for 3 courses.  Each course 
consists of cisplatin (Day #1), gemcitab ine (Day #1), ALT -801 (Day #3 & 
Day #5), gemcitabine (Day #8), ALT -801 (Day #8 & Day #10), and a rest 
period (Days #11- 21). Prior to commencing the second or the third course, 
subjects will need to meet the continuation criteria. At the completion of the 
three full courses of study treatment, each patient enrolled will have been 
scheduled to have a total of [ADDRESS_436324] stable disease and meet other 
treatment criteria will repeat study treatment with four additional weekly doses of ALT -801.  Delays or modifications are addressed in the protocol. 
This is illustrated in the following schemas:  
 Initial Study Treatment:  
 
 
 
 
Repeat Study Treatment:  
 
 
 
Enrolled patients will receive the study treatment at qualified cancer 
treatment centers with adequate diagnostic and treatment facilities to provide appropriate management of therapy and complications. ALT -801, cisplatin 
and gemcitabine will be administered by [CONTACT_351113] a central or peripheral vein under the supervision of a qualified physician experienced 
in the use of anti -cancer agents including  aldesleukin (Proleukin
), cisplatin 
and gemcitabine. 
This is the schema for the dose levels during the dose -escalation phase of the 
study.  The -1 and - 2 dose levels of ALT -801 are included in case of DLT 
events in the initial dose level.  
Cohort  ALT- 801 Dose (mg/kg)  Cisplatin  (mg/m2) Gemcitabine (mg/m2) 
-2 0.01 70 1000  
-1 0.02 70 1000  
1 (initial)  0.[ADDRESS_436325] 
Period  Gemcitabine  X   X  X   X  X   X  
ALT -801  X X X X  X X X X  X X X X 
Dose#  1 2 3 4 
Repeat  
Treatment Day  1 8 15 22 
ALT -801 X X X X 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 02  
IND 100174                                 July 8, 2011  
Page  9 of 71 Dose Escalation:  In this phase of the study, a minimum of 3 patients will be enrolled at each 
dose level.  All patients will be monitored for Dose Limiting Toxicity (DLT) for 8 weeks from the initial dose.  If 0/[ADDRESS_436326] a DLT that is drug -related, that dose 
level will be designated as exceeding the maximum tolerated d ose. If there 
are 3 patients in the dose level below this level, then additional patients (up to 6 total) will be enrolled at that dose level. When there is a dose level with 0 or 1 out of 6 patients with DLT, which is either the maximum planned dose level  (level 5) or which is one level below a dose that was not tolerated, 
the dose that is the maximum tolerated dose will be considered defined. Further changes in the treatment plan may be considered by [CONTACT_351119].  
If more than two of s ix patients experience a DLT at the initial dose level 
(level 1), then the sponsor, the Data Safety Monitoring Board and the principal investigators will meet to determine how to adjust downward the dose level of cisplatin, gemcitabine, and/or the study drug, or continue with the (-1) and (-2) cohorts, and to determine how to proceed with the study.  
Dose limiting toxicity (DLT) is defined as any toxicity of grade 3 that does not resolve to Grade 1 or lower within 72 hours and any toxicity of Grade 4 occurr ing during treatment courses with exceptions and details described in 
the study protocol. Patients experiencing a DLT should discontinue study 
treatment.  Study treatment discontinuation due to adverse events experienced prior to study drug administration, disease progression or 
patient’s decision to withdraw from study treatment without occurrence of any study treatment discontinuation event will not necessarily define a DLT event.  Study treatment discontinuation events are defined in the protocol.  
Dose Expansion : The two -stage expansion phase at the MTD will be conducted using a 
modified Simon two -stage design (1, 2) .  Both objective response (OR) 
(defined as complete response (CR) + partial response (PR)) and clinical benefit (CB) (defined as CR, PR + stable disease (SD)) will be evaluated and common set thresholds of lack of efficacy (OR rate (ORR) = 40%; CB rate (CBR) = 78%) and an efficacy level of interest (ORR = 60%; CBR = 92%) will be selected.  The sample size was driven by [CONTACT_351115].      
Stoppi[INVESTIGATOR_10020]:  The patient enrollment will be temporarily suspended based on occurrence of any the following, and the sponsor, the Data Safety Monitoring Board and principal investigators will meet to discuss how to proceed with future patient enrollment in the study:  
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 02  
IND 100174                                 July 8, 2011  
Page  10 of 71 • If at any time the dose escalation phase of the study, more than one 
patient in a cohort of three, or two of six patients experience any DLT; 
• If at any time during the expansion phase of the study, more than 33% the patients exp erience any drug related DLT.  
Evaluations: Patients will be evaluated for clinical toxicities during the treatment.  Patients’ blood samples will be collected to assess the pharmacokinetic profile and immunogenicity of the study drug. The anti -tumor response will 
be evaluated for up to [ADDRESS_436327] one dose of the study drug ALT -
801 will be included in the anti -tumor response evaluation.  Between each 
cohort and at the end of the study, all clinical and safety data will be analyzed for all patients enrolled in the study for dose- response effects.  
Population:  Patients of [ADDRESS_436328] an Eastern Cooperative Oncology Group (ECOG) performance status of [ADDRESS_436329] 12 weeks.  
Sample Size:  A total of up to 30 assessable  patients will be accrued to the initial dose 
escalation phase of the study (Phase Ib); the estimated number is 21.  Up to an additional 40 assessable patients will be enrolled at the expansion phase 
(Stage 1 and 2) of the study (Phase II) .  A total of approximately 61 
assessable patients will be enrolled and complete the study.  Ass ume a 20% 
ineligible or non - assessable cases, a total of up 72 patients may be accrued 
to the study. 
Primary  
Endpoints:  
For Stage I only:  (1) To define an MTD of ALT-801 in combination with cisplatin and 
gemcitabine in the treatment of patients with muscle invasive or metastatic urothelial cancer.  
For Stage I & II:  (2) To assess the safety of the combination study treatment in treated patients.  
 (3) To assess the objective response rate in treated patients.  
Secondary  
Endpoints:  (1) To assess the progressi on free survival in treated patients.  
(2) To assess the overall survival in treated patients.  
(3) To evaluate the immunogenicity and pharmacokinetic profiles of ALT-
801 in treated patients. 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 02  
IND 100174                                 July 8, 2011  
Page  11 of 71 (4) To assess the relationship between tumor presentation of HLA -
A*0201/p53 aa 264-272 complexes and the safety and clinical benefit of 
study treatment.  
Pharmacokinetics  
& Biomarkers:  Blood samples will be collected to assess typi[INVESTIGATOR_22588] -A2, immune cell 
levels, phenotype, pharmacokinetics, immunogenicity of the study drug 
ALT -801, and the serum levels of IFN -γ and TNF -α.  Tumor samples will  
be collected to test HLA -A*0201/p53 aa 264- [ADDRESS_436330] course of study 
treatment. Ven ous blood will be obtained at Time 0 (before the start of 
infusion), at 30 minutes (15 minutes after completion of infusion), and 1, [ADDRESS_436331] and second courses of study treatment.  HLA -A2 typi[INVESTIGATOR_351102]. 
Monitoring Tests:  Urine samples  for urinalysis, blood samples for standard chemistry, CBC, 
differential and coagulation will be obtained at screening, on each study drug infusion day, discharge days and follow -up visits.  Blood samples for 
immunogenicity testing, which include assays fo r anti -ALT -[ADDRESS_436332] ALT -
801 infusion day and at Week 9 from the initial dose of study treatment.  
Anti -tumor  
Response  
Evaluation: The anti -tumor response will be evaluated for up to 18 weeks from the initial 
dose of study treatment: for non -responders: Week 9 and 13; for early 
responders: Week 9 and 14; for late responders: Week 9, 13 and 18. 
Objective Response will be evaluated using the new international criteria 
proposed by [CONTACT_941] R esponse Evaluation Criteria in Solid Tumors Committee 
(RECIST) 1.1.  Baseline evaluations should be performed up to [ADDRESS_436333] of the treatment.  However, 
cystoscopic evaluation may be used routinely in this population, in addition to radiologic testing.  
Survival  
Assessment:  Progression- free survival and overall survival of all enrolled patients will be 
assessed at 6, 9, 12, 18, 24, 30 and 36 months from the start of study 
treatment, or through the point designated as the end of the study follow up. 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 02  
IND 100174                                 July 8, 2011  
Page  12 of 71 Adverse Events:  All patients will be monitored and evaluated for clinical toxicities during the 
treatment period and queried at each follow -up visit for Adverse Events 
(AEs).  Patients may volunteer information concerning AEs.  All adverse events will be graded by [CONTACT_351117] 4.0 (CTCAE v4.0), and logged in the patient Case Report Form.  The study centers should report all SAEs and all events that trigger patient’s study treatment discontinuation to the sponsor via phone, fax or email (or a combination) up to 1 day after learning of the event.  The sponsor will use the information to manage and coordinate the dose escalation, cohort expansion and patient enrollment.  The sponsor will then inform all of the participating clinical sites of the current dose level and the number of patients to be enrolled at that level, or of any patient enrollment suspension via phone, fax or email within a day of its learning of the event.  The study centers should report the other adverse events to the sponsor following the guidelines defined in the study protocol. All study drug related adverse events (AEs) that are both serious and unexpected will be report ed 
to the FDA in an expedited manner in accordance with 21 CFR §312.32. 
Statistical Plan:  For  each cohort, all AEs will be tabulated and examined and all safety and 
pharmacokinetic data will be evaluated. For estimation of duration of 
response, the Kaplan- Meier method will be used. P -values of < 0.05 (two-
sided) will be considered to indicate statistical significance.   
 
CA-ALT -801-01-10 CONFIDENTIAL                              Version#: 02  
IND 100174                                                  July 8, 2011  
Page 42 of 71 8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS 
8.1 Study calendar  
TESTS & PROCEDURES  SCREEN1 INITIAL TREATMENT PE RIOD  SCAN #1  SCAN #2  REPEAT 
TREATMENT  SCAN #3  FOLLOW -UPS  
COURSE 1  COURSE 2  COURSE 3  
Month (late responders in parentheses)   1 2 3 4 3 – 4/(4-5) 4/(5)  
  
  
  6 
  
  9 12 18 24 30 36 
Week (late responders in parentheses)   1 2 3 4 5 6 7 8 9 13 10/ 
(14) 11/ 
(15) 12/ 
(16) 13/ 
(17) 14/ 
(18)        
Week Day   M W F  M W  M W F M W  M W F M W     M M  M  M         
Treatment Day   1 3 5 8 10  22 24 26 29 31  43 45 47 50 52                     
Informed consent   X       
R 
e 
s 
t 
 
P 
e 
r 
i 
o 
d 
       
R 
e 
s 
t 
 
P 
e r 
i 
o 
d 
                    
Medical history  X                              
Serum pregnancy test2 X                              
Complete physical exam  X X     X     X     X X X      X        
Vital signs, weight, Height3 X X X X X X X X X X X X X X X X X X X X X X X        
Concurrent medication  X X X X X X X X X X X X X X X X X X X X X X X        
CBC with Differential, Blood Chemistry  X X X X X X X X X X X X X X X X X X X X X X X        
Coagulation (PT/INR)4 X                              
Urinalysis  X X      X     X       X            
Cardiac functions5 X X5 X X X X X5 X X X X X5 X X X X     X5 X X X         
Pulmonary functions  X                              
Adverse event assessment6 X X X X  X X X X X X X X X X X X X X X X X X X        
Tumor assessment7 X                   X X     X        
Survival Assessment8                          X X X X X X X 
HLA A2 Typi[INVESTIGATOR_007],  immune cell levels & phenotype11   X9      X9                       
HLA -A*0201/p53 tumor typi[INVESTIGATOR_007]    X                            
PK, IFNγ, TNFα11   X10                              
Immunogenicity tests11   X12               X                    
Cisplatin   c1     c2     c3                   
Gemcitabine   g1   g2  g3   g4  g5   g6                
Study drug (ALT -801    a1 a2 a3 a4   a5 a6 a7 a8   a9 a10 a11 a12     a13 a14 a15 a16         
1Screening evaluations are performed < 14 days , scan/x -ray < 28 days  prior to start of therapy.  If the patient's condition is deteriorating, laboratory evaluations should be repeated within [ADDRESS_436334] is for women with childbearing potential only.  3Vital signs (especially blood pressure), clinical status and laboratory tests should be reviewed before start of therapy. Vit al signs will be evaluated every 2 
hours after the drug treatment and before discharge, and body weight before study treatment infusion on study treatment infusion  day. 4PT/INR  should be performed for any bleeding issues.  5Patients are closely monitored for 
hypotension, arrhythmia, angina and myocardial infarction. At screening, patients who are ≥ [ADDRESS_436335] (stress 
thallium, stress MUGA or dobutamine echocardiogram) to determine their eligibility for parti cipation in the study. EKG will be performed at start of each treatment course and the repeat study drug treatment course. At the start of 
1st course, EKG is performed only when >[ADDRESS_436336] an on -going study drug -related SAE  upon study completion or at discontinuation of the study will be contact[CONTACT_33981]/her 
designee every week until the event is resolved or determined to be irreversible. 7Tumor response and progression will be evaluated in this study using the new international criteria proposed by [CONTACT_39694] (1.1). 8Information about 
tumor assessment & other therapi[INVESTIGATOR_351103]  9Fresh blood samples for HLA A2 blood typi[INVESTIGATOR_007], immune cell lev els & phenotype  testing will be collected before dosing. 
10Collect blood samples at Time 0 (before drug infusion), at 30 min (15 min after completion of infusion, +/ - 5 min), 1 hour (+/ - 10 min), 3 hour (+/ - 30 min), 6 hour (+/ - 60 min) from Time 0. IFN γ and TNFα assays are performed 
using the same samples and at the same schedule as PK .  11Residual samples may be used by [CONTACT_351118]. 12Use the same blood sample collected before dosing for PK test. 
 
 
 
CLINICAL STUDY PROTOCOL  
 
 
Protocol Number:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
 
  
Date of Protocol:   
Version # 01  
Version  # 02 
Version # [ADDRESS_436337]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 
   
   INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
  
Date of Protocol:   
Version# 01  
Version# 02 
Version # [ADDRESS_436338]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 By [CONTACT_12006], I hereby [CONTACT_205286] I have read, and that I understand and will abide by 
[CONTACT_22138], instructions, and restrictions contained in the attached protocol. 
 
Additionally, I will not initiate this study without approval of the appropriate Institutional 
Review Boar d (IRB), and I understand that any changes in the protocol must be approved in 
writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to subjects.  
  
   
Principal Investig ator’s Signature   [CONTACT_351125]’s Name (Print)    
   
   
   
CA-ALT -801-01-10 CONFIDENTIAL              Version#: 03  
IND 100174    November 10, 2011  
 
Page 3 of 72 
 Table of Contents 
SYNOPSIS  ........................................................................................................................................ 7 
1. OBJECTIVES  ........................................................................................................................ 13 
1.1 P RIMARY OBJECTIVES  ....................................................................................................... 13 
1.2 S ECONDARY OBJECTIVES  .................................................................................................. 13 
2. BACKGROUND  .................................................................................................................... 13 
2.1 ALT -801  – GENERAL INFORMATION  ................................................................................ 13 
2.2 B LADDER CANCER  ............................................................................................................ 13 
2.3 I MMUNOTHERAPY  ............................................................................................................. 14 
2.4 I NTRATUMORAL TARGETIN G AND P 53 AS A TARGET FOR BIO THERAPY  .............................. 14 
2.5 P53 AS A THERAPEUTIC TA RGET FOR BLADDER CANCER  .................................................... 16 
2.6 IN VITRO CHARACTERIZATION AND  TUMOR EFFICACY STUD IES IN ANIMAL MODELS  .......... 16 
2.6.1 Efficacy evaluation of ALT-801 dose regimens in xenograft tumor models ............ 17 
2.6.2 Efficacy of ALT -801 and non- targeted scTCR/IL -[ADDRESS_436339] human p53-negative orthotropic murine bladder 
tumors in immunocompetent mice. .......................................................................................... 19 
2.7 N ON-CLINICAL TOXICOLOGY  ............................................................................................ 20 
2.7.1 Single-dose toxicity study ......................................................................................... 20 
2.7.2 Multi-dose toxicity study .......................................................................................... 20 
2.8 P HARMACOKINETICS  ......................................................................................................... 21 
2.8.1 Non-clinical pharmacokinetics ................................................................................ 21 
2.8.2 Clinical pharmacokinetics ....................................................................................... 21 
2.9 H UMAN EXPERIENCE  ......................................................................................................... 22 
2.9.1 Pharmacodynamics .................................................................................................. 22 
2.9.2 Tumor assessment  .................................................................................................... 22 
2.9.3 Safety results  ............................................................................................................ 23 
2.9.4 Repeat treatment  ...................................................................................................... 24 
3. RAT
IONALE FOR THE CURRENT STUDY ................................................................... 24 
4. OVERALL STUDY DESIGN  ............................................................................................... 25 
5. STUDY POPULATION ........................................................................................................ 27 
5.1 I NCLUSION CRITERIA  ......................................................................................................... 27 
5.2 E XCLUSION CRITERIA  ........................................................................................................ 27 
5.3 I NCLUSION OF  WOMEN AND MINORITIES ............................................................................ 28 
6. STUDY DESIGN .................................................................................................................... 29 
6.1 S TUDY FLOW DIAGRAM  ..................................................................................................... 29 
6.2 S CREENING AND ENROLLM ENT ......................................................................................... 29 
6.3 S TUDY TREATMENT ........................................................................................................... 29 
6.3.1 Treatment setting  ..................................................................................................... 30 
6.3.2 Treatment regimen  ................................................................................................... 30 
6.3.3 Pre-therapy interventions ........................................................................................ 31 
CA-ALT -801-01-10 CONFIDENTIAL              Version#: 03  
IND 100174    November 10, 2011  
 
Page 4 of 72 
 [IP_ADDRESS] Pre-medication and IV fluids for A LT-801 ......................................................... 31 
[IP_ADDRESS] Pre-medication and IV fluids for cisplatin ........................................................... 32 
[IP_ADDRESS] Pre-medication and IV fluids for gemcitabine ..................................................... 32 
6.3.4 Study drug preparation and administration ............................................................ 32 
[IP_ADDRESS] ALT -801 .............................................................................................................. 32 
[IP_ADDRESS] Cisplatin  ............................................................................................................... 32 
[IP_ADDRESS] Gemcitabine  ......................................................................................................... 32 
6.4 D URATION OF PATIENT P ARTICIPATION  ............................................................................. 32 
6.5 D OSE ESCALATION  ............................................................................................................ 33 
6.6 E XPANSION AT MTD  ........................................................................................................ 33 
6.7 S TOPPI[INVESTIGATOR_16442]  ............................................................................................................... 34 
6.8 P ATIENT MONITORING , ANTI -TUMOR RESPONSE EVALU ATION , SURVIVAL ASSESSMENT  .... 34 
6.8.1 Patient monitoring ................................................................................................... 34 
6.8.2 Anti-tumor response evaluation ............................................................................... 34 
6.8.3 Survival assessment ................................................................................................. 35 
6.9 D OSE LIMITING TOXICITIES  ............................................................................................... 35 
6.10 S TUDY TREATMENT DISCO NTINUATION ............................................................................. 35 
6.10.1 Study treatment discontinuation events ................................................................... 35 
6.10.2 Follow-ups after treatment discontinuation............................................................. 35 
[IP_ADDRESS]. Discontinuation due to SAEs or on-going study drug related AEs ................. 35 
[IP_ADDRESS]. Discontinuation due to any other reasons ........................................................ 36 
6.11 S TUDY TREATMENT ADJUS TMENT  ..................................................................................... 36 
6.11.1 Kidney dysfunction ................................................................................................... 36 
6.11.2 Hematological dysfunction ...................................................................................... 36 
6.11.3 Hypotension ............................................................................................................. 37 
6.11.4 Allergic reactions and cytokine release syndrome/acute infusion reaction ............ [ADDRESS_436340] COURSES OF STUDY TREATMENT  ....................................................... 37 
6.12.1 Qualification  ............................................................................................................ 37 
6.12.2 Treatment schedule and procedures ........................................................................ 38 
6.13 R EPEAT STUDY DRUG TRE ATMENT  .................................................................................... 38 
6.13.1 Qualification  ............................................................................................................ 38 
6.13.2 Treatment s chedule and procedures ........................................................................ 38 
6.14 G ENERAL SUPPORTIVE CA RE GUIDELINES AND DRUG INTERACTION  .................................. 38 
6.14.1 ALT-801 ................................................................................................................... 38 
[IP_ADDRESS]. Hypotension and capi[INVESTIGATOR_12737] ....................................................... 38 [IP_ADDRESS]. Pulmonary dysfunction .................................................................................... 39 [IP_ADDRESS]. Impaired kidney and liver functions ................................................................ 39 [IP_ADDRESS]. Infection  ........................................................................................................... 39 
[IP_ADDRESS]. Fever and chills ................................................................................................ 39 [IP_ADDRESS]. Gastritis  ............................................................................................................ 39 
[IP_ADDRESS]. Diarrhea, nausea and vomiting ........................................................................ 39 [IP_ADDRESS]. Pruritus a nd dermatitis  ..................................................................................... 40 
[IP_ADDRESS]. Acidosis............................................................................................................ 40 [IP_ADDRESS]. Life-threatening toxicities  ................................................................................ 40 
[IP_ADDRESS]. Other supportive care ....................................................................................... 40 
CA-ALT -801-01-10 CONFIDENTIAL              Version#: 03  
IND 100174    November 10, 2011  
 
Page 5 of 72 
 [IP_ADDRESS]. Drug interaction  ............................................................................................... 40 
6.14.2 Cisplatin  ................................................................................................................... 41 
6.14.3 Gemcitabine ............................................................................................................. 41 
7. STUDY DRUG: AVAILABILITY, ACCOUNTABILITY, PACKAGING & 
LABELING  .................................................................................................................................... 42 
7.1 ALT -801 .......................................................................................................................... 42 
7.1.1 Availability  ............................................................................................................... 42 
7.1.2 Accountability .......................................................................................................... 42 
7.1.3 Packaging ................................................................................................................ 42 
7.1.4 Labeling ................................................................................................................... 42 
7.2 C ISPLATIN AND GEMCITABINE  .......................................................................................... 42 
8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS ........................................ 43 
8.1 S TUDY CALENDAR  ............................................................................................................ 43 
8.2 P ROCEDURE AND TESTS  .................................................................................................... 44 
8.2.1 HLA -A2 typi[INVESTIGATOR_351101] .......................... 44 
8.2.2 Presentation of HLA-A*0201/p53 aa264-[ADDRESS_436341]  .......................................................................................................... 44 
8.2.5 Physical examination ............................................................................................... 44 
8.2.6 Vital signs, body weight & height ............................................................................ 44 
8.2.7 Cardiac assessment .................................................................................................. 44 
8.2.8 Blood tests ................................................................................................................ 45 
8.2.9 Urinalysis  ................................................................................................................. 45 
8.2.10 Pulmonary functions ................................................................................................ 45 
8.2.11 Adverse event assessment  ........................................................................................ 45 
8.2.12 Tumor assessment  .................................................................................................... 45 
8.2.13 Survival assessment ................................................................................................. 45 
8.2.14 Pharmacokinetic (PK) testing .................................................................................. [ADDRESS_436342] overall response ......................................................................... 49 
9.4 C ONFIRMATORY  ................................................................................................................ 50 
CA-ALT -801-01-10 CONFIDENTIAL              Version#: [ADDRESS_436343] ING, REPORTING AND COMMUNICATION  .................................. 52 
11.2 A DVERSE EVENT TERMINO LOGY AND DEFINITIONS  ........................................................... 53 
11.3 A DVERSE EVENT REPORTING PROCEDURES  ...................................................................... 54 
11.4 A DVERSE EVENT EXPEDITED REPORTING GUIDELINES  ..................................................... 54 
11.5 S UBMISSION OF SERIOUS  ADVERSE EVENT REPOR TING  ...................................................... 54 
11.6 D ATA REPORTING FORMS  ................................................................................................. 55 
11.7 R EPORT /DATA SUBMISSION ADDRE SS & CONTACT  ........................................................... 55 
11.8 P ATIENT RECORDS , QUALITY ASSURANCE , RECORDS RETENTION  ...................................... 56 
11.9 M ETHOD O F REVIEW  ......................................................................................................... 56 
11.10 S PECIAL REGULATORY CO NSIDERATIONS  ...................................................................... 56 
11.10.1 HIPAA  .................................................................................................................. 56 
11.10.2 Protocol amendments, informed consent, and IRB approval .............................. 57 
12. CONFIDENTIALITY  ....................................................................................................... 57 
13. ETHICAL STANDARDS & INVESTIGATOR OBLIGATIONS  ................................ [ADDRESS_436344] OF EXPECTED ADVERSE EVENTS  .................................................................. 58 
15. CTCAE ................................................................................................................................ 60 
REF
ERENCES  ............................................................................................................................... 61 
APPENDIX A: PERFORMANCE STATUS CRITERIA.......................................................... 64 
APPENDIX B: NEW YORK  HEART ASSOCIATION CLASSIFICATION ......................... 64 
APPENDIX C: ETHICAL STANDARDS  ................................................................................... 65 
APPENDIX D: INVESTIGATOR OBLIGATIONS  .................................................................. 66 
APPENDIX E: CONTACT [CONTACT_351110] - ALTOR  ............................................................................... 70 
APPENDIX F: CONTACT [CONTACT_351110] – DATA SAFETY MONITORING BOARD (DSM B) ...... 71 
APPENDIX G: CONTACT L IST - LABORATORIES  ............................................................. 71 
APPENDIX H: APPROVAL  PAGE  ............................................................................................ 72 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 03  
IND 100174                                  November 10, 2011  
Page 7 of 72 SYNOPSIS  
Sponsor:  Altor Bioscience Corporation 
Protocol#: CA-ALT -801-01-10 
Study Drug Name:  [CONTACT_351126]:  ALT -801 (c264scTCR- IL2), recombinant humanized, soluble single -chain 
TCR -cytokine fusion protein; Cisplatin; Gemcitabine.  
Study Type:  Interventional 
Study Phase:  Ib/II 
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combina tion with Cisplatin and 
gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer  
Objectives:    To determine the safety and tolerability of the novel combination of addition 
of ALT -801 (c264scTCR -IL2) to the doublet of cisplatin and gemcitabine in 
patients with muscle invasive or metastatic urothelial cancer of bladder, 
renal pelvis, ureters and urethra.   
To estimate the anti- tumor activity of this combination of ALT -801, 
cisplatin and gemcitabine by [CONTACT_351111]- tumor response, 
progr ession free survival (assessed through end of study), and overall 
survival (assessed through end of study) in treated patients.  
To characterize the immunogenicity and pharmacokinetic profile of ALT -
801 in combination with cisplatin and gemcitabine in trea ted patients.  
To assess the relationship between tumor presentation of HLA -A*0201/p53 
aa 264 -272 complex and the safety and clinical benefit of study treatment. 
Study Design:  This is a Phase Ib/II, open- label, multi- center, competitive enrollment and 
dose- escalation study of ALT -[ADDRESS_436345] muscle invasive or metastatic 
urothelial cancer of bladder, renal pelvis, ureters and urethra.  The study will be conducted in conformity wit h Good Clinical Practice (GCP).  
The study includes a dose escalation phase to determine the maximum tolerated dose (MTD) of ALT -801 in combination with cisplatin and 
gemcitabine and a two -stage expansion phase at the MTD.  The dose 
escalation in this stud y is conducted using a (3+3) dose escalation design, 
and the two- stage expansion phase at the MTD using a modified Simon two -
stage design (1, 2).  In the dose escalation phase of this study, there are five dose levels of ALT -801 (0.04 mg/kg, 0.06 mg/kg and 0.08 mg/kg, 0.10 
mg/kg and 0 .12 mg/kg) in addition to two de -escalation dose levels.  The 
doses of cisplatin (70 mg/m
2/dose) and gemcitabine (1000 mg/m2/dose) will 
be fixed across all ALT -[ADDRESS_436346] and the principal investigators will meet to discuss whether to amend the protocol to expand the dose escalation phase to include additional ALT -801 
dose levels.  
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 03  
IND 100174                                  November 10, 2011  
Page 8 of 72 Treatments:  The planned initial on- study treatment will be for 3 courses.  Each course 
consists of cisplatin (Day #1), gemcitabine (Day #1), ALT -801 (Day #3 & 
Day #5), gemcitabine (Day #8), ALT -801 (Day #8 & Day #10), and a rest 
period (Days #11- 21). Prior to commencing the second or the third course, 
subjects will need  to meet the continuation criteria. At the completion of the 
three full courses of study treatment, each patient enrolled will have been 
scheduled to have a total of [ADDRESS_436347] stable disease and meet other treatment criteria will repeat study treatment with four additional weekly doses of ALT -801.  Delays or modifications are addressed in the protocol.  
This is illustrated in the following schemas:  
 Initial Study Treatment:  
 
 
 
 
Repeat Study Treatment:  
 
 
 
Enrolled patients will receive the study treatment at qualified cancer 
treatment centers with adequate diagnostic and treatment facilities to provide appropriate management of therapy and complications. ALT -801, cisplatin 
and gemcitabine will be administered by [CONTACT_351113] a central or peripheral vein under the supervision of a qualified ph ysician experienced 
in the use of anti -cancer agents including aldesleukin (Proleukin
), cisplatin 
and gemcitabine. 
This is the schema for the dose levels during the dose -escalation phase of the 
study.  The -1 and - 2 dose levels of ALT -801 are included in case of DLT 
events in the initial dose level.  
Cohort  ALT- 801 Dose (mg/kg)  Cisplatin  (mg/m2) Gemcitabine (mg/m2) 
-2 0.01 70 1000  
-1 0.02 70 1000  
1 (initial)  0.[ADDRESS_436348] 
Period  Gemcitabine  X   X  X   X  X   X  
ALT -801  X X X X  X X X X  X X X X 
Dose#  1 2 3 4 
Repeat  
Treatment Day  1 8 15 22 
ALT -801 X X X X 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 03  
IND 100174                                  November 10, 2011  
Page 9 of 72 Dose Escalation:  In this phase of the study, a minimum of 3 patients will be enrolled at each 
dose level.  All patients will be monitored for Dose Limiting Toxicity (DLT) for 8 weeks from the initial dose.  If 0/[ADDRESS_436349] a DLT that is drug -related, that dose 
level will be designated as exceeding the maximum tolerated dose. If there are 3 patients in the dose level below this level, then additional patients (up to 6 total) will be enrolled at that dose level. When there is a dose level with 0 or 1 out of 6 pat ients with DLT, which is either the maximum planned 
dose level (level 5) or which is one level below a dose that was not tolerated, the dose that is the maximum tolerated dose will be considered defined. Further changes in the treatment plan may be considered by [CONTACT_351119].  
If more than two of six patients experience a DLT at the initial dose level (level 1), then the sponsor, the Data Safety Monitoring Board and the principal investigators will meet to determine how to adjust downward  the 
dose level of cisplatin, gemcitabine, and/or the study drug, or continue with the (-1) and (-2) cohorts, and to determine how to proceed with the study.  
Dose limiting toxicity (DLT) is defined as any toxicity of grade 3 that does not resolve to Grade  1 or lower within 72 hours and any toxicity of Grade 4 
occurring during treatment courses with exceptions and details described in the study protocol. Patients experiencing a DLT should discontinue study 
treatment.  Study treatment discontinuation due to adverse events experienced prior to study drug administration, disease progression or patient’s decision to withdraw from study treatment without occurrence of any study treatment discontinuation event will not necessarily define a DLT event.  Study treatment discontinuation events are defined in the protocol.  
Dose Expansion : The two -stage expansion phase at the MTD will be conducted using a 
modified Simon two -stage design (1, 2) .  Both objective response (OR) 
(defined as complete response (CR) + partial response (PR)) and clinical benefit (CB) (defined as CR, PR + stable disease (SD)) will be evaluated and 
common set thresholds of lack of efficacy (OR rate (ORR) = 40%; CB rate (CBR) = 78%) and an efficacy level of interest (ORR = 60%; CBR = 92%) will be selected.  The sample size was driven by [CONTACT_351115].      
Stoppi[INVESTIGATOR_10020]:  The patient enrollment will be temporarily suspended based on occurrence of any the following, and the sponsor, the Data Safety Monitoring Board and principal inves tigators will meet to discuss how to proceed with future 
patient enrollment in the study:  
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 03  
IND 100174                                  November 10, 2011  
Page 10 of 72 • If at any time the dose escalation phase of the study, more than one 
patient in a cohort of three, or two of six patients experience any DLT; 
• If at any time during th e expansion phase of the study, more than 33% 
the patients experience any drug related DLT.  
Evaluations: Patients will be evaluated for clinical toxicities during the treatment.  Patients’ blood samples will be collected to assess the pharmacokinetic profi le and immunogenicity of the study drug. The anti -tumor response will 
be evaluated for up to [ADDRESS_436350] one dose of the study drug ALT -
801 will be included in the anti -tumor response evaluation.  Between each 
cohort and at the end of the study, all clinical and safety data will be analyzed for all patients enrolled in the study for dose- response effects.  
Population:  Patients of [ADDRESS_436351] an Eastern Cooperative Oncology Group (ECOG) performance status of [ADDRESS_436352] 12 weeks.  
Sample Size:  A total of up to 30 assessable  patients will be  accrued to the initial dose 
escalation phase of the study (Phase Ib); the estimated number is 21.  Up to an additional 40 assessable patients will be enrolled at the expansion phase 
(Stage 1 and 2) of the study (Phase II) .  A total of approximately 60 
assessable patients will be enrolled and complete the study.  Assume a 20% 
ineligible or non - assessable cases, a total of up 72 patients may be accrued 
to the study. 
Primary  
Endpoints:  
For Stage I only:  (1) To define an MTD of ALT-801 in combination with cisplatin and 
gemcitabine in the treatment of patients with muscle invasive or metastatic urothelial cancer.  
For Stage I & II:  (2) To assess the safety of the combination study treatment in treated patients.  
 (3) To assess the objective response rate in treated patients.  
Secondary  
Endpoints:  (1) To assess the progression free survival in treated patients.  
(2) To assess the overall survival in treated patients.  
(3) To evaluate the immunogenicity and pharmacokinetic profiles of ALT-
801 in treated patients. 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 03  
IND 100174                                  November 10, 2011  
Page 11 of 72 (4) To assess th e relationship between tumor presentation of HLA -
A*0201/p53 aa 264-272 complexes and the safety and clinical benefit of 
study treatment.  
Pharmacokinetics  
& Biomarkers:  Blood samples will be collected to assess typi[INVESTIGATOR_22588] -A2, immune cell 
levels, phenotype, pharmacokinetics, immunogenicity of the study drug 
ALT -801, and the serum levels of IFN -γ and TNF -α.  Tumor samples will  
be collected to test HLA -A*0201/p53 aa 264- [ADDRESS_436353] course of study 
treatment. Ven ous blood will be obtained at Time 0 (before the start of 
infusion), at 30 minutes (15 minutes after completion of infusion), and 1, [ADDRESS_436354] and second courses of study treatment.  HLA -A2 typi[INVESTIGATOR_351102]. 
Monitoring Tests:  Urine samples  for urinalysis, blood samples for standard chemistry, CBC, 
differential and coagulation will be obtained at screening, on each study drug infusion day, discharge days and follow -up visits.  Blood samples for 
immunogenicity testing, which include assays fo r anti -ALT -[ADDRESS_436355] ALT -
801 infusion day and at Week 9 from the initial dose of study treatment.  
Anti -tumor  
Response  
Evaluation: The anti -tumor response will be evaluated for up to 18 weeks from the initial 
dose of study treatment: for non -responders: Week 9 and 13; for early 
responders: Week 9 and 14; for late responders: Week 9, 13 and 18. 
Objective Response will be evaluated using the new international criteria 
proposed by [CONTACT_941] R esponse Evaluation Criteria in Solid Tumors Committee 
(RECIST) 1.1.  Baseline evaluations should be performed up to [ADDRESS_436356] of the treatment.  However, 
cystoscopic evaluation may be used routinely in this population, in addition to radiologic testing.  
Survival  
Assessment:  Progression- free survival and overall survival of all enrolled patients will be 
assessed at 6, 9, 12, 18, 24, 30 and 36 months from the start of study 
treatment, or through the point designated as the end of the study follow up. 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 03  
IND 100174                                  November 10, 2011  
Page 12 of 72 Adverse Events:  All patients will be monitored and evaluated for clinical toxicities during the 
treatment period and queried at each follow -up visit for Adverse Events 
(AEs).  Patients may volunteer information concerning AEs.  All adverse events will be graded by [CONTACT_351117] 4.0 (CTCAE v4.0), and logged in the patient Case Report Form.  The study centers should report all SAEs and all events that trigger patient’s study treatment discontinuation to the sponsor via phone, fax or email (or a combination) up to 1 day after learning of the event.  The sponsor will use the information to manage and coordinate the dose escalation, cohort expansion and patient enrollment.  The sponsor will then inform all of the participating clinical sites of the current dose level and the number of patients to be enrolled at that level, or of any patient enrollment suspension via phone, fax or email within a day of its learning of the event.  The study centers should report the other adverse events to the sponsor following the guidelines defined in the study protocol. All study drug related adverse events (AEs) that are both serious and unexpected will be report ed 
to the FDA in an expedited manner in accordance with 21 CFR §312.32. 
Statistical Plan:  For each cohort, all AEs will be tabulated and examined and all safety and pharmacokinetic data will be evaluated. For estimation of duration of 
response, the Kaplan- Meier method will be used. P -values of < 0.05 (two-
sided) will be considered to indicate statistical significance.   
 
CA-ALT -801-01-10 CONFIDENTIAL                              Version#: 03  
IND 100174                                                   November 10, 2011  
Page 43 of 72 8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS 
8.1 Study calendar  
TESTS & PROCEDURES  SCREEN1 INITIAL TREATMENT PE RIOD  SCAN #1  SCAN #2  REPEAT 
TREATMENT  SCAN #3  FOLLOW -UPS  
COURSE 1  COURSE 2  COURSE 3  
Month (late responders in parentheses)   1 2 3 4 3 – 4/(4-5) 4/(5)  
  
  
  6 
  
  9 12 18 24 30 36 
Week (late responders in parentheses)   1 2 3 4 5 6 7 8 9 13 10/ 
(14) 11/ 
(15) 12/ 
(16) 13/ 
(17) 14/ 
(18)        
Week Day   M W F  M W  M W F M W  M W F M W     M M  M  M         
Treatment Day   1 3 5 8 10  22 24 26 29 31  43 45 47 50 52                     
Informed consent   X       
R 
e 
s 
t 
 
P 
e 
r 
i 
o 
d 
       
R 
e 
s 
t 
 
P 
e r 
i 
o 
d 
                    
Medical history  X                              
Serum pregnancy test2 X                              
Complete physical exam  X X     X     X     X X X      X        
Vital s igns, weight, Height3 X X X X X X X X X X X X X X X X X X X X X X X        
Concurrent medication  X X X X X X X X X X X X X X X X X X X X X X X        
CBC with Differential, Blood Chemistry  X X X X X X X X X X X X X X X X X X X X X X X        
Coagu lation (PT/INR)4 X                              
Urinalysis  X X      X     X       X            
Cardiac functions5 X X5 X X X X X5 X X X X X5 X X X X     X5 X X X         
Pulmonary functions  X                              
Adverse event assessmen t6 X X X X  X X X X X X X X X X X X X X X X X X X        
Tumor assessment7 X                   X X     X        
Survival Assessment8                          X X X X X X X 
HLA A2 Typi[INVESTIGATOR_007],  immune cell levels & phenotype11   X9      X9                       
HLA -A*0201/p53 tumor typi[INVESTIGATOR_007]    X                            
PK, IFNγ, TNFα11   X10                              
Immunogenicity tests11   X12               X                    
Cisplatin   c1     c2     c3                   
Gemcitabine   g1   g2  g3   g4  g5   g6                
Study drug (ALT -801    a1 a2 a3 a4   a5 a6 a7 a8   a9 a10 a11 a12     a13 a14 a15 a16         
1Screening evaluations are performed < 14 days , scan/x -ray < 28 days  prior to start of therapy.  If the patient's  condition is deteriorating, laboratory evaluations should be repeated within [ADDRESS_436357] is for women with childbearing potential only.  3Vital signs (especially blood pressure), clinical status and laboratory tests should be reviewed before start of therapy. Vital signs will be evaluated every 2 
hours after the drug treatment and before discharge, and body weight before study treatment infusion on study treatment infus ion day. 4PT/INR  should b e performed for any bleeding issues.  5Patients are closely monitored for 
hypotension, arrhythmia, angina and myocardial infarction. At screening, patients who are ≥ [ADDRESS_436358] (stress 
thallium, stress MUGA or dobutamine echocardiogram) to determine their eligibility for parti cipation in the study. EKG will be performed at start of each treatment course and the repeat study drug treatment course. At the start of 
1st course, EKG is performed only when >[ADDRESS_436359] an on -going study drug -related SAE  upon study completion or at discontinuation of the study will be contact[CONTACT_33981]/her 
designee every week until the event is resolved or determined to be irreversible. 7Tumor response and progression will be evaluated in this study using the new international criteria proposed by [CONTACT_39694] (1.1). 8Information about 
tumor assessment & other therapi[INVESTIGATOR_351103]  9Fresh blood samples for HLA A2 blood typi[INVESTIGATOR_007], immune cell lev els & phenotype  testing will be collected before dosing. 
10Collect blood samples at Time 0 (before drug infusion), at 30 min (15 min after completion of infusion, +/ - 5 min), 1 hour (+/ - 10 min), 3 hour (+/ - 30 min), 6 hour (+/ - 60 min) from Time 0. IFN γ and TNFα assays are performed 
using the same samples and at the same schedule as PK .  11Residual samples may be used by [CONTACT_351118]. 12Use the same blood sample collected before dosing for PK test. 
 
 
 
CLINICAL STUDY PROTOCOL  
 
 
Protocol Number:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
 
  
Date of Protocol:   
Version # 01  
Version  # 02 
Version # 03 
Version # [ADDRESS_436360]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 
   
   INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
  
Date of Protocol:   
Version  # 01 
Version # 02 
Version # 03 Version # [ADDRESS_436361]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety D ata Fax:  [PHONE_7261]  
  
 By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by [CONTACT_22138], instructions, and restrictions contained in the attached protocol. 
 
Additionally, I will not initiate this study  without approval of the appropriate Institutional 
Review Board (IRB), and I understand that any changes in the protocol must be approved in 
writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to subjects.  
  
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    
   
   
   
CA-ALT -801-01-10 CONFIDENTIAL              Version#: 04  
IND 100174    December 23, 2011  
 
Page 3 of 72 
 Table of Contents 
SYNOPSIS  ........................................................................................................................................ 7 
1. OBJECTIVES  ........................................................................................................................ 13 
1.1 P RIMARY OBJECTIVES  ....................................................................................................... 13 
1.2 S ECONDARY OBJECTIVES  .................................................................................................. 13 
2. BACKGROUND  .................................................................................................................... 13 
2.1 ALT -801  – GENERAL INFORMATION  ................................................................................ 13 
2.2 B LADDER CANCER  ............................................................................................................ 13 
2.3 I MMUNOTHERAPY  ............................................................................................................. 14 
2.4 I NTRATUMORAL TARGETIN G AND P 53 AS A TARGET FOR BIO THERAPY  .............................. 14 
2.5 P53 AS A THERAPEUTIC TA RGET FOR BLADDER CANCER  .................................................... 16 
2.6 IN VITRO CHARACTERIZATION AND  TUMOR EFFICACY STUD IES IN ANIMAL MODELS  .......... 16 
2.6.1 Efficacy evaluation of ALT-801 dose regimens in xenograft tumor models ............ 17 
2.6.2 Efficacy of ALT -801 and non- targeted scTCR/I L-[ADDRESS_436362] human p53-negative orthotropic murine bladder 
tumors in immunocompetent mice. .......................................................................................... 19 
2.7 N ON-CLINICAL TOXICOLOGY  ............................................................................................ 20 
2.7.1 Single-dose toxicity study ......................................................................................... 20 
2.7.2 Multi-dose toxicity study .......................................................................................... 20 
2.8 P HARMACOKINETICS  ......................................................................................................... 21 
2.8.1 Non-clinical pharmacokinetics ................................................................................ 21 
2.8.2 Clinical pharmacokinetics ....................................................................................... 21 
2.9 H UMAN EXPERIENCE  ......................................................................................................... 22 
2.9.1 Pharmacodynamics .................................................................................................. 22 
2.9.2 Tumor assessment  .................................................................................................... 22 
2.9.3 Safety results  ............................................................................................................ 23 
2.9.4 Repeat treatment  ...................................................................................................... 24 
3. RAT
IONALE FOR THE CURRENT STUDY ................................................................... 24 
4. OVERALL STUDY DESIGN  ............................................................................................... 25 
5. STUDY POPULATION ........................................................................................................ 27 
5.1 I NCLUSION CRITERIA  ......................................................................................................... 27 
5.2 E XCLUSION CRITERIA  ........................................................................................................ 28 
5.3 I NCLUSION OF WOMEN AND MINORITIES ............................................................................ 28 
6. STUDY DESIGN .................................................................................................................... 29 
6.1 S TUDY FLOW DIAGRAM  ..................................................................................................... 29 
6.2 S CREENING AND ENROLLM ENT ......................................................................................... 29 
6.3 S TUDY TREATMENT ........................................................................................................... 29 
6.3.1 Treatment setting  ..................................................................................................... 30 
6.3.2 Treatment regimen  ................................................................................................... 30 
6.3.3 Pre-therapy interventions ........................................................................................ 31 
CA-ALT -801-01-10 CONFIDENTIAL              Version#: 04  
IND 100174    December 23, 2011  
 
Page 4 of 72 
 [IP_ADDRESS] Pre-medication and IV fluids for ALT-801 ......................................................... 31 
[IP_ADDRESS] Pre-medication and IV fluids for cisplatin ........................................................... 32 
[IP_ADDRESS] Pre-medication and IV fluids for gemcitabine ..................................................... 32 
6.3.4 Study drug preparation and administration ............................................................ 32 
[IP_ADDRESS] ALT -801 .............................................................................................................. 32 
[IP_ADDRESS] Cisplatin  ............................................................................................................... 32 
[IP_ADDRESS] Gemcitabine  ......................................................................................................... 32 
6.4 D URATION OF PATIENT PARTICIPATION  ............................................................................. 32 
6.5 D OSE ESCALATION  ............................................................................................................ 33 
6.6 E XPANSION AT MTD  ........................................................................................................ 33 
6.7 S TOPPI[INVESTIGATOR_16442]  ............................................................................................................... 34 
6.8 P ATIENT MONITORING , ANTI -TUMOR RESPONSE EVALU ATION , SURVIVAL ASSESSMENT  .... 34 
6.8.1 Patient monitoring ................................................................................................... 34 
6.8.2 Anti-tumor response evaluation ............................................................................... 34 
6.8.3 Survival assessment ................................................................................................. 35 
6.9 D OSE LIMITING TOXICITIES  ............................................................................................... 35 
6.10 S TUDY TREATMENT DISCO NTINUATION ............................................................................. 35 
6.10.1 Study treatment discontinuation events ................................................................... 35 
6.10.2 Follow-ups after treatment discontinuation............................................................. 35 
[IP_ADDRESS]. Discontinuation due to SAEs or on-going study drug related AEs ................. 35 
[IP_ADDRESS]. Discontinuation due to any other reasons ........................................................ 36 
6.11 S TUDY TREATMENT ADJUS TMENT  ..................................................................................... 36 
6.11.1 Kidney dysfunction ................................................................................................... 36 
6.11.2 Hematological dysfunction ...................................................................................... 36 
6.11.3 Hypotension ............................................................................................................. 37 
6.11.4 Allergic reactions and cytokine release syndrome/acute infusion reaction ............ [ADDRESS_436363] COURSES OF STUDY TREATMENT  ....................................................... 37 
6.12.1 Qualification  ............................................................................................................ 37 
6.12.2 Treatment schedule and procedures ........................................................................ 38 
6.13 R EPEAT STUDY DRUG TRE ATMENT  .................................................................................... 38 
6.13.1 Qualification  ............................................................................................................ 38 
6.13.2 Treatment schedule and procedures ........................................................................ 38 
6.14 G ENERAL SUPPORTIVE CA RE GUIDELINES AND DRUG INTERACTION  .................................. 38 
6.14.1 ALT-801 ................................................................................................................... 38 
[IP_ADDRESS]. Hypotension and capi[INVESTIGATOR_12737] ....................................................... 38 [IP_ADDRESS]. Pulmonary dysfunction .................................................................................... 39 [IP_ADDRESS]. Impaired kidney and liver functions ................................................................ 39 [IP_ADDRESS]. Infection  ........................................................................................................... 39 
[IP_ADDRESS]. Fever and chills ................................................................................................ 39 [IP_ADDRESS]. Gastritis  ............................................................................................................ 39 
[IP_ADDRESS]. Diarrhea, nausea and vomiting ........................................................................ 39 [IP_ADDRESS]. Pruritus and dermatitis  ..................................................................................... 39 
[IP_ADDRESS]. Acidosis............................................................................................................ 40 [IP_ADDRESS]. Life-threatening  toxicities  ................................................................................ 40 
[IP_ADDRESS]. Other supportive care ....................................................................................... 40 
CA-ALT -801-01-10 CONFIDENTIAL              Version#: 04  
IND 100174    December 23, 2011  
 
Page 5 of 72 
 [IP_ADDRESS]. Drug interaction  ............................................................................................... 40 
6.14.2 Cisplatin  ................................................................................................................... 41 
6.14.3 Gemcitabine ............................................................................................................. 41 
7. STUDY DRUG: AVAILABILITY, ACCOUNTABILITY, PACKAGING & 
LABELING  .................................................................................................................................... 42 
7.1 ALT -801 .......................................................................................................................... 42 
7.1.1 Availability  ............................................................................................................... 42 
7.1.2 Accountability .......................................................................................................... 42 
7.1.3 Packaging ................................................................................................................ 42 
7.1.4 Labeling ................................................................................................................... 42 
7.2 C ISPLATIN AND GEMCITABINE  .......................................................................................... 42 
8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS ........................................ 43 
8.1 S TUDY CALENDAR  ............................................................................................................ 43 
8.2 P ROCEDURE AND TESTS  .................................................................................................... 44 
8.2.1 HLA -A2 typi[INVESTIGATOR_351101] .......................... 44 
8.2.2 Presentation of HLA -A*0201/p53 aa264-[ADDRESS_436364]  .......................................................................................................... 44 
8.2.5 Physical examination ............................................................................................... 44 
8.2.6 Vital signs, body weight & height ............................................................................ 44 
8.2.7 Cardiac assessment  .................................................................................................. 44 
8.2.8 Blood tests ................................................................................................................ 45 
8.2.9 Urinalysis  ................................................................................................................. 45 
8.2.10 Pulmonary functions ................................................................................................ 45 
8.2.11 Adverse event assessment  ........................................................................................ 45 
8.2.12 Tumor assessment  .................................................................................................... 45 
8.2.13 Survival assessment ................................................................................................. 46 
8.2.14 Pharmacokinetic (PK) testing .................................................................................. [ADDRESS_436365] overall response ......................................................................... 49 
9.4 C ONFIRMATORY  ................................................................................................................ 50 
CA-ALT -801-01-10 CONFIDENTIAL              Version#: [ADDRESS_436366] ING, REPORTING AND COMMUNICATION  .................................. 52 
11.2 A DVERSE EVENT TERMINO LOGY AND DEFINITIONS  ........................................................... 53 
11.3 A DVERSE EVENT REPORTING PROCEDURES  ...................................................................... 54 
11.4 A DVERSE EVENT EXPEDITED REPORTING GUIDELINES  ..................................................... 54 
11.5 S UBMISSION OF SERIOUS  ADVERSE EVENT REPOR TING  ...................................................... 54 
11.6 D ATA REPORTING FORMS  ................................................................................................. 55 
11.7 R EPORT /DATA SUBMISSION ADDRE SS & CONTACT  ........................................................... 55 
11.8 P ATIENT RECORDS , QUALITY ASSURANCE , RECORDS RETENTION  ...................................... 56 
11.9 M ETHOD OF REVIEW  ......................................................................................................... 56 
11.10 S PECIAL REGULATORY CO NSIDERATIONS  ...................................................................... 56 
11.10.1 HIPAA .................................................................................................................. 56 
11.10.2 Protocol amendments, informed consent, and IRB approval .............................. 57 
12. CONFIDENTIALITY  ....................................................................................................... 57 
13. ETHICAL STANDARDS & INVESTIGATOR OBLIGATIONS  ................................ [ADDRESS_436367] OF EXPECTED ADVERSE EVENTS  .................................................................. 58 
15. CTCAE ................................................................................................................................ 60 
REF
ERENCES  ............................................................................................................................... 61 
APPENDIX A: PERFORMANCE STATUS CRITERIA.......................................................... 64 
APPENDIX B: NEW YORK  HEART ASSOCIATION CLASSIFICATION ......................... 64 
APPENDIX C: ETHICAL STANDARDS  ................................................................................... 65 
APPENDIX D: INVESTIGATOR OBLIGATIONS  .................................................................. 66 
APPENDIX E: CONTACT [CONTACT_351110] - ALTOR  ............................................................................... 70 
APPENDIX F: CONTACT [CONTACT_351110] – DATA SAFETY MONITORING BOARD (DSM B) ...... 71 
APPENDIX G: CONTACT [CONTACT_351110] - LABORATORIES  ............................................................. 71 
APPENDIX H: APPROVAL  PAGE  ............................................................................................ 72 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 04  
IND 100174                                  December 23, 2011  
Page 7 of 72 SYNOPSIS  
Sponsor:  Altor Bioscience Corporation 
Protocol#: CA-ALT -801-01-10 
Study Drug Name:  [CONTACT_351126]:  ALT -801 (c264scTCR- IL2), recombinant humanized, soluble single -chain 
TCR -cytokine fusion protein; Cisplatin; Gemcitabine.  
Study Type:  Interventional 
Study Phase:  Ib/II 
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination with Cisplatin and 
gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer  
Objectives:    To determine the safety and tolerability of the novel combination of addition 
of ALT -801 (c264scTCR -IL2) to the doublet of cisplatin and gemcitabine in 
patients with muscle invasive or metastatic urothelial cancer of bladder, renal pelvis, ureters and urethra.   
To estimate the anti- tumor activity of this combination of ALT -801, 
cisplatin and gemcitabine by [CONTACT_351111]- tumor response, 
progression free survival (assessed through end of study), and overall 
survival (assessed through end of study) in treated patients.  
To characterize the immunogenicity and pharmacokinetic profile of  ALT-
801 in combination with cisplatin and gemcitabine in treated patients. To assess the relationship between tumor presentation of HLA -A*0201/p53 
aa 264 -272 complex and the safety and clinical benefit of study treatment. 
Study Design:  This is a Phase Ib/ II, open -label, multi- center, competitive enrollment and 
dose- escalation study of ALT -[ADDRESS_436368] muscle invasive or metastatic 
urothelial cancer of bladder, renal pelvis, ureters and urethra.  The study will be conducted in conformity with Good Clinical Practice (GCP).  
The study includes a dose escalation phase to determine the maximum 
tolerated dose (MTD) of ALT -801 in combination with cisplatin and 
gemcitabine and a two -stage expansion phase at the MTD.  The dose 
escalation in this study is conducted using a (3+3) dose escalation design, and the two- stage expansion phase at the MTD using a modified Simon two -
stage design (1, 2).  In the dose escalation phase of this study, there are five dose levels of AL T-801 (0.04 mg/kg, 0.06 mg/kg and 0.08 mg/kg, 0.10 
mg/kg and 0.12 mg/kg) in addition to two de -escalation dose levels.  The 
doses of cisplatin (70 mg/m
2/dose) and gemcitabine (1000 mg/m2/dose) will 
be fixed across all ALT -[ADDRESS_436369] and the principal investigators will meet to discuss whether to amend the protocol to expand the dose escalation phase to include additional ALT -801 
dose levels.  
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 04  
IND 100174                                  December 23, 2011  
Page 8 of 72 Treatments:  The planned initial on- study treatment will be for 3 courses.  Each course 
consists of cisplatin (Day #1), gemcitabine (Day #1), ALT -801 (Day #3 & 
Day #5), gemcitabine (Day #8), ALT -801 (Day #8 & Day #10), and a rest 
period (Days #11- 21). Prior to commencing the second or the third course, 
subjects will need to meet the continuation criteria. At the completion of the 
three full courses of study treatment, each patient enrolled will have been scheduled to have a total of [ADDRESS_436370] stable disease and meet other treatment criteria will repeat study treatment with four additional weekly doses of AL T-801.  Delays or modifications are addressed in the protocol. 
This is illustrated in the following schemas:  
 Initial Study Treatment:  
 
 
 
 
Repeat Study Treatment:  
 
 
 
Enrolled patients will receive the stu dy treatment at qualified cancer 
treatment centers with adequate diagnostic and treatment facilities to provide 
appropriate management of therapy and complications. ALT -801, cisplatin 
and gemcitabine will be administered by [CONTACT_351113] a cent ral 
or peripheral vein under the supervision of a qualified physician experienced 
in the use of anti -cancer agents including aldesleukin (Proleukin), cisplatin 
and gemcitabine. 
This is the schema for the dose levels during the dose -escalation phase of the 
study.  The -1 and - 2 dose levels of ALT -801 are included in case of DLT 
events in the initial dose level.  
Cohort  ALT- 801 Dose (mg/kg)  Cisplatin  (mg/m2) Gemcitabine (mg/m2) 
-2 0.01 70 1000  
-1 0.02 70 1000  
1 (initial)  0.[ADDRESS_436371] 
Period  Gemcitabine  X   X  X   X  X   X  
ALT -801  X X X X  X X X X  X X X X 
Dose#  1 2 3 4 
Repeat  
Treatment Day  1 8 15 22 
ALT -801 X X X X 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 04  
IND 100174                                  December 23, 2011  
Page 9 of 72 Dose Escalation:  In this phase of the study, a minimum of 3 patients will be enrolled at each 
dose l evel.  All patients will be monitored for Dose Limiting Toxicity (DLT) 
for 8 weeks from the initial dose.  If 0/[ADDRESS_436372] a DLT that is drug -related, that dose 
level will be designated as exceeding the maximum tolerated dose. If there are 3 pat ients in the dose level below this level, then additional patients (up 
to 6 total) will be enrolled at that dose level. When there is a dose level with 0 or 1 out of 6 patients with DLT, which is either the maximum planned dose level (level 5) or which is one level below a dose that was not tolerated, the dose that is the maximum tolerated dose will be considered defined. Further changes in the treatment plan may be considered by [CONTACT_351119].  
If more than two of six patients experience a DLT at the initial dose level (level 1), then the sponsor, the Data Safety Monitoring Board and the principal investigators will meet to determine how to adjust downward the dose level of cisplatin, gemcitabine, and/or the study drug, or continue with the (-1) and (-2) cohorts, and to determine how to proceed with the study.  
Dose limiting toxicity (DLT) is defined as any toxicity of grade 3 that does not resolve to Grade 1 or lower within 72 hours and any toxicity of Grade 4 occurring during treatment courses with exceptions and details described in the study protocol. Patients experiencing a DLT should discontinue study 
treatment.  Study treatment discontinuation due to adverse events experienced prior to study drug administration, disease progression or  
patient’s decision to withdraw from study treatment without occurrence of any study treatment discontinuation event will not necessarily define a DLT event.  Study treatment discontinuation events are defined in the protocol.  
Dose Expansion : The two -stage expansion phase at the MTD will be conducted using a 
modified Simon two -stage design (1, 2) .  Both objective response (OR) 
(defined as complete response (CR) + partial response (PR)) and clinical benefit (CB) (defined as CR, PR + stable disease (SD)) will be evaluated and common set  thresholds of lack of efficacy (OR rate (ORR) = 40%; CB rate 
(CBR) = 78%) and an efficacy level of interest (ORR = 60%; CBR = 92%) will be selected.  The sample size was driven by [CONTACT_351115].      
Stoppi[INVESTIGATOR_56906]:  The patient enrollment will be temporarily suspended based on occurrence of any the following, and the sponsor, the Data Safety Monitoring Board and principal investigators will meet to discuss how to proceed with future patient enrollment in the study:  
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 04  
IND 100174                                  December 23, 2011  
Page 10 of 72 • If at any time the dose escalation phase of the study, more than one 
patient in a cohort of three, or two of six patients experience any DLT; 
• If at any time during the expansion phase of the study, more than 33% the patients experience any drug related DLT.  
Evaluations: Patients will be evaluated for clinical toxicities during the treatment.  Patients’ blood samples will be collected to assess the pharmacokinetic profile and immunogenicity of the study drug. The anti -tumor response will 
be evaluated fo r up to [ADDRESS_436373] one dose of the study drug ALT -
801 will be included in the anti -tumor response evaluation.  Between each 
cohort and at the end of the study, all cli nical and safety data will be 
analyzed for all patients enrolled in the study for dose- response effects.  
Population:  Patients of [ADDRESS_436374] an Eastern Cooperative Oncology Group (ECOG) performance status of [ADDRESS_436375] 12 weeks.  
Sample Size:  A total of up to 30 assessable  patients will be accrued to the initial dose 
escalation phase of the study (Phase Ib); the estimated number is 21.  Up to an additional 40 assessable patients will be enrolled at the expansion phase 
(Stage 1 and 2) of the study (Phase II) .  A total of approximately 60 
assessable patients will be enrolled and complete the study.  Assume a 20% ineligible or  non- assessable cases, a total of up 72 patients may be accrued 
to the study. 
Primary  
Endpoints:  
For Stage I only:  (1) To define an MTD of ALT-801 in combination with cisplatin and 
gemcitabine in the treatment of patients with muscle invasive or metastatic urothelial cancer.  
For Stage I & II:  (2) To assess the safety of the combination study treatment in treated patients.  
 (3) To assess the objective response rate in treated patients.  
Secondary  
Endpoints:  (1) To assess the progression free survival in tre ated patients.  
(2) To assess the overall survival in treated patients.  
(3) To evaluate the immunogenicity and pharmacokinetic profiles of ALT-
801 in treated patients. 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 04  
IND 100174                                  December 23, 2011  
Page 11 of 72 (4) To assess the relationship between tumor presentation of HLA -
A*0201/p53 aa 264- 272 complexes and the safety and clinical benefit of 
study treatment.  
Pharmacokinetics  
& Biomarkers:  Blood samples will be collected to assess typi[INVESTIGATOR_22588] -A2, immune cell 
levels, phenotype, pharmacokinetics, immunogenicity of the study drug 
ALT -801, and the serum levels of IFN -γ and TNF -α.  Tumor samples 
obtained from surgeries or biopsies performed prior to screening for the 
study will be collected to test the HLA -A*0201/p53 aa 264- [ADDRESS_436376] course of 
study treatment. Venous blood will be obtained at Time 0 (before the start of infusion), at 30 minutes (15 minutes after completion of infusion), and 1, [ADDRESS_436377] and second courses of study treatment.  HLA -A2 typi[INVESTIGATOR_351102]. 
Monitoring Tests:  Urine samples  for urinalysis, blood samples for standard chemistry, CBC, 
differential and coagulation will be obtained at screening, on each study drug infusion day, discharge days and follow -up visits.  Blood samples for 
immunogenicity testing, which include assays fo r anti -ALT -[ADDRESS_436378] ALT -
801 infusion day and at Week 9 from the initial dose of study treatment.  
Anti -tumor  
Response  
Evaluation: The anti -tumor response will be evaluated for up to 18 weeks from the initial 
dose of study treatment: for non -responders: Week 9 and 13; for early 
responders: Week 9 and 14; for late responders: Week 9, 13 and 18. 
Objective Response will be evaluated using the new international criteria 
proposed by [CONTACT_941] R esponse Evaluation Criteria in Solid Tumors Committee 
(RECIST) 1.1.  Baseline evaluations should be performed up to [ADDRESS_436379] of the treatment.  However, 
cystoscopic evaluation may be used routinely in this population, in addition to radiologic testing.  If surgeries or biopsies are performed after patients receive and respond to study treatment, tumor or tissue samples from these procedures will be collected to assess histopathological and immuno- cellular 
responses to study treatment. 
 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 04  
IND 100174                                  December 23, 2011  
Page 12 of 72 Survival  
Assessment:  Progression- free survival and overall survival of all enrolled patients will be 
assessed at 6, 9, 12, 18, 24, 30 and 36 months from the start of study 
treatment, or through the point designated as the end of the study follow up. 
Adverse Events:  All patients will be monitored and evaluated for clinical toxicities during the treatment period and queried at each follow -up visit for Adverse Events 
(AEs).  Patients may volunteer information concerning AEs.  All adverse 
events will be graded by [CONTACT_351117] 4.0 (CTCAE v4.0), and logged in the patient Case Report Form.  The study centers should report all SAEs and all events that trigger patient’s study treatment discontinuation to the sponsor via phone, 
fax or email (or a combination) up to 1 day after learning of the event.  The sponsor will use the information to manage and coordinate the dose escalation, cohort expansion and patient enrollment.  The sponsor will then inform all of the participating clinical sites of the current dose level and the number of patients to be enrolled at that level, or of any patient enrollment suspension via phone, fax or email within a day of its learning of the event.  The study centers should report the other adverse events to the sponsor following the guidelines defined in the study protocol. All study drug related adverse events (AEs) that are both serious and unexpected will be reported 
to the FDA in an expedited manner in accordance with 21 CFR §312.32. 
Statistical Plan:  For each cohort, all AEs will be tabulated and examined and all safety and pharmacokinetic data will be evaluated. For estimation of duration of 
response, the Kaplan- Meier method will be used. P -values of < 0.05 (two-
sided) will be considered to indicate statistical significance.   
 
CA-ALT -801-01-10 CONFIDENTIAL                              Version#: 04  
IND 100174                                                   December 23, 2011  
Page 43 of 72 8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS 
8.1 Study calendar  
TESTS & PROCEDURES  SCREEN1 INITIAL TREATMENT PE RIOD  SCAN #1  SCAN #2  REPEAT 
TREATMENT  SCAN #3  FOLLOW -UPS  
COURSE 1  COURSE 2  COURSE 3  
Month (late responders in parentheses)   1 2 3 4 3 – 4/(4-5) 4/(5)  
  
  
  6 
  
  9 12 18 24 30 36 
Week (late responders in parentheses)   1 2 3 4 5 6 7 8 9 13 10/ 
(14) 11/ 
(15) 12/ 
(16) 13/ 
(17) 14/ 
(18)        
Week Day   M W F  M W  M W F M W  M W F M W     M M  M  M         
Treatment Day   1 3 5 8 10  22 24 26 29 31  43 45 47 50 52                     
Informed consent   X       
R 
e 
s 
t 
 
P 
e 
r 
i 
o 
d 
       
R 
e 
s 
t 
 
P 
e r 
i 
o 
d 
                    
Medical history  X                              
Serum pregnancy test2 X                              
Complete physical exam  X X     X     X     X X X      X        
Vital s igns, weight, Height3 X X X X X X X X X X X X X X X X X X X X X X X        
Concurrent medication  X X X X X X X X X X X X X X X X X X X X X X X        
CBC with Differential, Blood Chemistry  X X X X X X X X X X X X X X X X X X X X X X X        
Coagu lation (PT/INR)4 X                              
Urinalysis  X X      X     X       X            
Cardiac functions5 X X5 X X X X X5 X X X X X5 X X X X     X5 X X X         
Pulmonary functions  X                              
Adverse event assessmen t6 X X X X  X X X X X X X X X X X X X X X X X X X        
Tumor assessment7 X                   X X     X        
Survival Assessment8                          X X X X X X X 
HLA A2 Typi[INVESTIGATOR_007],  immune cell levels & phenotype11   X9      X9                       
HLA -A*0201/p53 tumor typi[INVESTIGATOR_007]    X                            
PK, IFNγ, TNFα11   X10                              
Immunogenicity tests11   X12               X                    
Cisplatin   c1     c2     c3                   
Gemcitabine   g1   g2  g3   g4  g5   g6                
Study drug (ALT -801)13    a1 a2 a3 a4   a5 a6 a7 a8   a9 a10 a11 a12     a13 a14 a15 a16         
1Screening evaluations are performed < 14 days , scan/x -ray < 28 days  prior to start of therapy.  If the patien t's condition is deteriorating, laboratory evaluations should be repeated within [ADDRESS_436380] is for women with childbearing potential only.  3Vital signs (especially blood pressure), clinical s tatus and laboratory tests should be reviewed before start of therapy. Vital signs will be evaluated every 2 
hours after the drug treatment and before discharge, and body weight before study treatment infusion on study treatment infus ion day. 4PT/INR  shoul d be performed for any bleeding issues.  5Patients are closely monitored for 
hypotension, arrhythmia, angina and myocardial infarction. At screening, patients who are ≥ [ADDRESS_436381] (stress 
thallium, stress MUGA or dobutamine echocardiogram) to determine their eligibility for parti cipation in the study. EKG will be performed at start of each treatment course and the repeat study drug treatment course. At the start of 
1st course, EKG is performed only when >[ADDRESS_436382] an on -going study drug -related SAE  upon study completion or at discontinuation of the study will be contact[CONTACT_33981]/her 
designee every week until the event is resolved or determined to be irreversible. 7Tumor response and progression will be evaluated in this study using the new international criteria proposed by [CONTACT_39694] (1.1). 8Information about 
tumor assessment & other therapi[INVESTIGATOR_351103]  9Fresh blood samples for HLA A2 blood typi[INVESTIGATOR_007], immune cell lev els & phenotype  testing will be collected before dosing. 
10Collect blood samples at Time 0 (before drug infusion), at 30 min (15 min after completion of infusion, +/ - 5 min), 1 hour (+/ - 10 min), 3 hour (+/ - 30 min), 6 hour (+/ - 60 min) from Time 0. IFN γ and TNFα assays are performed 
using the same samples and at the same schedule as PK .  11Residual samples may be used by [CONTACT_351118]. 12Use the same blood sample collected before dosing for PK test.13On the days when 
gemc itabine and ALT -[ADDRESS_436383].  
 
 
 
CLINICAL STUDY PROTOCOL  
 
 
Protocol Number:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib /II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
 
  
Date of Protocol:   
Version # 01  
Version # 02 
Version # 03 Version # 04 Version # [ADDRESS_436384]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 
   
   INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
  
Date of Protocol:   
Version # 01  
Version # 02 
Version # 03 Version # 04 Version # [ADDRESS_436385]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by [CONTACT_22138], instructions, and restrictions contained in the attached protocol. 
 
Additionally, I will not initiate this study without approval of the ap propriate Institutional 
Review Board (IRB), and I understand that any changes in the protocol must be approved in 
writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to  subjects.  
  
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    
   
   
   
CA-ALT -801-01-10 CONFIDENTIAL              Version#: 05  
IND 100174            May 11, 2012  
 
Page 3 of 76 
 Table of Contents 
SYNOPSIS  ........................................................................................................................................ 7  
1. OBJECTIVES  ........................................................................................................................ 13  
1.1 PRIMARY OBJECTIVES  ....................................................................................................... 13  
1.2 SECONDARY OBJECTIVES  .................................................................................................. 13  
2. BACKGROUND  .................................................................................................................... 13  
2.1 ALT -801  – GENERAL INFORMATION  ................................................................................ 13  
2.2 BLADDER CANCER  ............................................................................................................ 13  
2.3 IMMUNOTHERAPY  ............................................................................................................. 14  
2.4 INTRATUMORAL TARGETIN G AND P 53 AS A TARGET FOR BIO THERAPY  .............................. 14  
2.5 P53 AS A THERAPEUTIC TA RGET FOR BLADDER CANCER  .................................................... 16  
2.6 IN VITRO CHARACTERIZATION AND  TUMOR EFFICACY STUD IES IN ANIMAL MODELS  .......... 16  
2.6.1  Efficacy evaluation of ALT-801 dose regimens in xenograft tumor models ................ 17  
2.6.2  Efficacy of ALT -801 and non- targeted scTCR/IL -[ADDRESS_436386]-therapy interventions ................................................................ 32  
CA-ALT -801-01-10 CONFIDENTIAL              Version#: 05  
IND 100174            May 11, 2012  
 
Page 4 of 76 
 6.3.4  Study drug preparation and administration ................................................................ 34  
[IP_ADDRESS]  ALT -801 .............................................................................................................. 34  
[IP_ADDRESS]  Cisplatin  ............................................................................................................... 34  
[IP_ADDRESS]  Gemcitabine  ......................................................................................................... [ADDRESS_436387] ............................................................................................................ 35  
6.7 STOPPI[INVESTIGATOR_16442]  ............................................................................................................... 35  
6.8 PATIENT MONITORING , ANTI -TUMOR RESPONSE EVALU ATION , SURVIVAL ASSESSMENT  .... 36  
6.8.1  Patient mo nitoring ....................................................................................................... 36  
6.8.2  Anti-tumor response evaluation ................................................................................... 36  
6.8.3  Survival assessment ..................................................................................................... 37  
6.9 DOSE LIMITING TOXICITIES  ............................................................................................... 37  
6.10  STUDY TREATMENT DISCO NTINUATION ............................................................................. 37  
6.10.1  Study treatment discontinuation events ................................................................... 37  
6.10.2  Follow-ups after treatment discontinuation............................................................. 38  
[IP_ADDRESS].  Discontinuation due to SAEs or on-going study drug related AEs ................. 38  
[IP_ADDRESS].  Discontinuation due to any other reasons ........................................................ 38  
6.11  STUDY TREATMENT ADJUS TMENT  ..................................................................................... 38  
6.11.1  Modifications & delays for creatinine clearance (kidney dysfunction) ................... 38  
[IP_ADDRESS].  On cycles that have treatment with cisplatin, gemcitabine and ALT -801 ....... 38  
[IP_ADDRESS].  On cycles that have only ALT -801 .................................................................. 39  
[IP_ADDRESS].  Interventions .................................................................................................... 39  
6.11.2  Hematological dysfunction ...................................................................................... 39  
[IP_ADDRESS].  On cycles that have treatment with cisplatin, gemcitabine and ALT -801 ....... 39  
[IP_ADDRESS].  On cycles that only have ALT -801 .................................................................. 40  
[IP_ADDRESS].  Transfusion and growth factor interventions ................................................... 40  
6.11.3  Hypotension ............................................................................................................. 41  
6.11.4  Allergic reactions and cytokine release syndrome/acute infusion reaction ............ [ADDRESS_436388] COURSES OF STUDY TREATMENT  ....................................................... 41  
6.12.1  Qualification  ............................................................................................................ 41  
6.12.2  Treatment schedule and procedures ........................................................................ 41  
6.13  REPEAT STUDY DRUG TRE ATMENT  .................................................................................... 41  
6.13.1  Qualification  ............................................................................................................ 41  
6.13.2  Treatment schedule and procedures ........................................................................ 42  
6.14  GENERAL SUPPORTIVE CA RE GUIDELINES AND DRUG INTERACTION  .................................. 42  
6.14.1  ALT-801 ................................................................................................................... 42  
[IP_ADDRESS].  Hypotension and capi[INVESTIGATOR_12737] ....................................................... 42  
[IP_ADDRESS].  Pulmonary dysfunction .................................................................................... 43  
[IP_ADDRESS].  Impaired kidney and liver functions ................................................................ 43  
[IP_ADDRESS].  Infection  ........................................................................................................... 43  
[IP_ADDRESS].  Fever and chills ................................................................................................ 43  
[IP_ADDRESS].  Gastritis  ............................................................................................................ 43  
[IP_ADDRESS].  Diarrhea, nausea and vomiting ........................................................................ 43  
[IP_ADDRESS].  Pruritus and dermatitis  ..................................................................................... 43  
CA-ALT -801-01-10 CONFIDENTIAL              Version#: 05  
IND 100174            May 11, 2012  
 
Page 5 of 76 
 [IP_ADDRESS].  Acidosis............................................................................................................ 43  
[IP_ADDRESS].  Life-threatening toxicities  ................................................................................ 43  
[IP_ADDRESS].  Other supportive care ....................................................................................... 44  
[IP_ADDRESS].  Drug interaction  ............................................................................................... 44  
6.14.2  Cisplatin  ................................................................................................................... 45  
6.14.3  Gemcitabine ............................................................................................................. 45  
7. STUDY DRUG: AVAILABILITY, ACCOUNTABILITY, PACKAGING & 
LABELING  .................................................................................................................................... 46  
7.1 ALT -801 .......................................................................................................................... 46  
7.1.1  Availability  ................................................................................................................... 46  
7.1.2  Acco untability  .............................................................................................................. 46  
7.1.3  Packaging .................................................................................................................... 46  
7.1.4  Labeling ....................................................................................................................... 46  
7.2 CISPLATIN AND GEMCITABINE  .......................................................................................... 46  
8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS ........................................ 47  
8.1 STUDY CALENDAR  ............................................................................................................ 47  
8.2 PROCEDURE AND TESTS  .................................................................................................... 48  
8.2.1  HLA -A2 typi[INVESTIGATOR_351101] .............................. 48  
8.2.2  Presentation of HLA-A*0201/p53 aa264-[ADDRESS_436389]  .............................................................................................................. 48  
8.2.5  Physical examination ................................................................................................... 48  
8.2.6  Vital signs, body weight & height ................................................................................ 48  
8.2.7  Cardiac assessment ...................................................................................................... 48  
8.2.8  Blood tests .................................................................................................................... 49  
8.2.9  Urinalysis  ..................................................................................................................... 49  
8.2.10  Pulmonary functions ................................................................................................ 49  
8.2.11  Adverse event assessment  ........................................................................................ 49  
8.2.12  Tumor assessment  .................................................................................................... 49  
8.2.13  Survival assessment ................................................................................................. 50  
8.2.14  Pharmacokinetic (PK) testing .................................................................................. 50  
8.2.15  Biomarker assays for IFN γ and TNF α .................................................................... 50  
8.2.16  Immunogenicity tests - detection of anti- ALT-801 and IL2-neutralizing antibodies
 50  
9. MEASUREMENT OF EFFEC T .......................................................................................... 50  
9.1 DEFINITIONS  ..................................................................................................................... 50  
9.1.1  Measurable disease ...................................................................................................... 51  
9.1.2  Non-measurable disease .............................................................................................. 51  
9.1.3  Target lesion ................................................................................................................ 52  
9.1.4  Non-target lesions ........................................................................................................ 52  
9.2 GUIDELINES FOR EVALUATION OF MEASURABLE D ISEASE  ................................................. 52  
9.3 RESPONSE CRITERIA  .......................................................................................................... 53  
9.3.1  Evaluation of target lesions ......................................................................................... 53  
9.3.2  Evaluation of non-target lesions .................................................................................. 53  
CA-ALT -801-01-10 CONFIDENTIAL              Version#: [ADDRESS_436390] ING, REPORTING AND COMMUNICATION  .................................. 56  
11.2  ADVERSE EVENT TERMINO LOGY AND DEFINITIONS  ........................................................... 57  
11.3  ADVERSE EVENT REPORTING PROCEDURES  ...................................................................... 58  
11.4  ADVERSE EVENT EXPEDITED REPORTING GUIDELINES  ..................................................... 58  
11.5  SUBMISSION OF SERIOUS  ADVERSE EVENT REPOR TING  ...................................................... 58  
11.6  DATA REPORTING FORMS  ................................................................................................. 59  
11.7  REPORT /DATA SUBMISSION ADDRE SS & CONTACT  ........................................................... 59  
11.8  PATIENT RECORDS , QUALITY ASSURANCE , RECORDS RETENTION  ...................................... 60  
11.9  METHOD OF REVIEW  ......................................................................................................... 60  
11.10  SPECIAL REGULATORY CO NSIDERATIONS  ...................................................................... 60  
11.10.1  HIPAA  ...................................................................................................................... 60  
11.10.2  Protocol amendments, informed consent, and IRB approval .................................. 61  
12. CONFIDENTIALITY  ....................................................................................................... 61  
13. ETHICAL STANDARDS & INVESTIGATOR OBLIGATIONS  ................................ [ADDRESS_436391] OF EXPECTED ADVERSE EVENTS  .................................................................. 62  
15. CTCAE ................................................................................................................................ 64  
REFERENCES  ............................................................................................................................... 65  
APPENDIX A: PERFORMANCE STATUS CRITERIA.......................................................... 68  
APPENDIX B: NEW YORK  HEART ASSOCIATION CLASSIFICATION ......................... 68  
APPENDIX C: ETHICAL STANDARDS  ................................................................................... 69  
APPENDIX D: INVESTIGATOR OBLIGATIONS  .................................................................. 70  
APPENDIX E: CONTACT [CONTACT_351110] - ALTOR  ............................................................................... 74  
APPENDIX F: CONTACT [CONTACT_351110] – DATA SAFETY MONITORING BOARD (DSM B) ...... 75  
APPENDIX G: CONTACT [CONTACT_351110] - LABORATORIES  ............................................................. 75  
APPENDIX H: APPROVAL  PAGE  ............................................................................................ 76  
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 05  
IND 100174                                           May 11, 2012  
Page 7 of 76 SYNOPSIS  
Sponsor:  Altor Bioscience Corporation 
Protocol#: CA-ALT -801-01-10 
Study Drug Name:  [CONTACT_351126]:  ALT -801 (c264scTCR- IL2), recombinant humanized, soluble single -chain 
TCR -cytokine fusion protein; Cisplatin; Gemcitabine.  
Study Type:  Interventional 
Study Phase:  Ib/II 
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination with Cisplatin and 
gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer  
Objectives:    To determine the safety and tolerability of the novel combination of addition 
of ALT -801 (c264scTCR -IL2) to the doublet of cisplatin and gemcitabine in 
patients with muscle invasive or metastatic urothelial cancer of bladder, renal pelvis, ureters and urethra.   
To estimate the anti- tumor activity of this combination of ALT -801, 
cisplatin and gemcitabine by [CONTACT_351111]- tumor response, 
progression free survival (assessed through end of study), and overall 
survival (assessed through end of study) in treated patients.  
To characterize the immunogenicity and pharmacokine tic profile of ALT -
801 in combination with cisplatin and gemcitabine in treated patients. To assess the relationship between tumor presentation of HLA -A*0201/p53 
aa 264 -272 complex and the safety and clinical benefit of study treatment. 
Study Design:  This is a Phase Ib/II, open -label, multi- center, competitive enrollment and 
dose- escalation study of ALT -[ADDRESS_436392] muscle invasive or metastatic 
urothelial cancer of bladder, renal  pelvis, ureters and urethra.  The study will 
be conducted in conformity with Good Clinical Practice (GCP).  
The study includes a dose escalation phase to determine the maximum 
tolerated dose (MTD)  and the recommended dose (RD)  for dose expansion  
of ALT -[ADDRESS_436393].  The dose escalation in this study is conducted 
using a (3+3) dose escalation design, and the two- stage expansion phase at 
the RD using a modified Simon two- stage design (1, 2).  In the dose 
escalation phase of this study, there are five dose levels of ALT -801 (0.04 
mg/kg, 0.06 mg/kg , 0.08 mg/kg, 0.10 mg/kg and 0.12 mg/kg) in addition to 
two de -escalation dose levels.  The doses of cisplatin (70 mg/m
2/dose) and 
gemcitabine (1000 mg/m2/dose) will be fixed across all ALT -[ADDRESS_436394] (DSMB) and the principal investigators will meet to 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 05  
IND 100174                                           May 11, 2012  
Page 8 of 76 discuss whether to amend the protocol to expand the dose escalation phase to 
include additional ALT-801 dose levels.  
Treatments:  The planned initial on- study treatment will be for 3 courses  of chemo -
immunotherapy .  Each course consists of cisplatin (Day #1), gemcitabine 
(Day #1), ALT -801 (Day #3 & Day #5), gemcitabine (Day #8), ALT -801 
(Day #8 & Day #12 or #15), and a rest period (Days #13 ( or #16) - #21). The 
alternative dosing day (Day #15) for the last dose (dose #4) of ALT -[ADDRESS_436395] stable disease 
and meet other treatment criteria will repeat study treatment with four additional weekly doses of ALT -801.  T reatment delays or dose 
modifications  or omissions  are addressed in the protocol. The treatment 
schedule is illustrated in the following schemas:  
 Initial Study Treatment:  
 
 
 
 
RRepeat Study Treatment:  
 
 
 
Enrolled patients will receive the study treatment at qualified cancer 
treatment centers with adequate diagnostic and treatment facilities to provide appropriate management of therapy and complications. ALT -801, cisplatin 
and gemcitabine will be administer ed by [CONTACT_351113] a central 
or peripheral vein under the supervision of a qualified physician experienced 
in the use of anti -cancer agents including aldesleukin (Proleukin
), cisplatin 
and gemcitabine. 
This is the schema for the dose levels during the dose -escalation phase of the 
study.  The -1 and - 2 dose levels of ALT -801 are included in case of DLT 
events in the initial dose level.  
Cohort  ALT -801 Dose (mg/kg)  Cisplatin  (mg/m2) Gemcitabine (mg/m2) 
-2 0.01 70 1000  
-1 0.02 70 1000  
1 (initial)  0.04 70 1000  
2 0.06 70 1000  
3 0.08 70 1000  
4 0.10 70 1000  
5 0.12 70 1000   Course 1  Course 2  Course 3  
Treatment Day 1 3 5 8 12(15)  13(16) -21 22 24 26 29 33(36) 34(37)-42 43 45 47 50 54(57) 
Cisplatin  X     
Rest 
Period  X     
Rest 
Period  X     
Gemcitabine  X   X  X   X  X   X  
ALT -801  X X X X  X X X X  X X X X 
Dose#  1 2 3 4 
Repeat  
Treatment Day  1 8 15 22 
ALT -801 X X X X 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 05  
IND 100174                                           May 11, 2012  
Page 9 of 76 Dose Escalation:  In this phase of the study, a minimum of 3 patients will be enrolled at each 
dose level.  All patients will be monitored for Dose Limiting Toxicity (DLT) for 8 weeks from the initial dose.  If 0/[ADDRESS_436396] a DLT that is drug -related, that dose 
level will be designated as exceeding the maximum tolerated dose. If there 
are 3 patients in the dose level below this level, then additional patients (up to 6 total) will be enrolled at that dose level. When there is a dose level with 0 or 1 out of 6 patie nts with DLT, which is either the maximum planned 
dose level (level 5) or which is one level below a dose that was not tolerated, the dose that is the maximum tolerated dose (MTD) will be considered 
defined. Further changes in the treatment plan may be considered by [CONTACT_351119].  
If more than two of six patients experience a DLT at the initial dose level 
(level 1), then the sponsor, the Data Safety Monitoring Board (DSMB)  and 
the principal investigators will meet to determine how to adjust downward the dose level of cisplatin, gemcitabine, and/or the study drug, or continue with the ( -1) and ( -2) cohorts, and to determine how to proceed with the 
study.  
At any time during the dose escalation phase of the study , whether or not  the 
MTD or the maximum planned escalating dose level is reached, the dose 
escalation phase may be concluded due to favorable anti -tumor effect 
observed in the  enrolled patients .  The DSMB wi ll recommend a dose level 
of ALT -801 (RD) for the dose expansion phase of the study. 
Dose limiting toxicity (DLT) is defined as any toxicity of grade 3 that does not resolve to Grade 1 or lower within 72 hours and any toxicity of Grade 4 occurring during treatment courses with exceptions and details described in the study protocol. Patients experiencing a DLT should discontinue study 
treatment.  Study treatment discontinuation due to adverse events experienced prior to study drug administration, disease progression or patient’s decision to withdraw from study treatment without occurrence of any study treatment discontinuation event will not necessarily define a DLT event.  Study treatment discontinuation events are defined in the protocol.  
Dose Expansion : T he two -stage expansion phase at the recommended dose (RD) will be 
conducted using a modified Simon two- stage design (1, 2) .  Both objective 
response (OR) (defined as complete response (CR) + partial response (PR)) and clinical benefit (CB) (defined as CR, PR + stable disease (SD)) wil l be 
evaluated and common set thresholds of lack of efficacy (OR rate (ORR) = 40%; CB rate (CBR) = 78%) and an efficacy level of interest (ORR = 60%; 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 05  
IND 100174                                           May 11, 2012  
Page 10 of 76 CBR = 92%) will be selected.  The sample size was driven by [CONTACT_351120].      
Stoppi[INVESTIGATOR_10020] s: The patient enrollment will be temporarily suspended based on occurrence of any the following, and the sponsor, the Data Safety Monitoring Board and principal investigators will meet to discuss how to proceed with futur e 
patient enrollment in the study:  
• If at any time during the dose escalation phase of the study,  
 more than one patient in a cohort of three, or two of six patients 
experience any DLT  or, 
 favorable anti -tumor response data collected from enrolled patients 
that indicates a dose level with significant therapeutic effect may 
have been found 
• If at any time during the expansion phase of the study, more than 33% the patients experience any drug related DLT.  
Evaluations: Patients will be evaluated for clinical toxicities during the treatment.  Patients’ blood samples will be collected to assess the pharmacokinetic profile and immunogenicity of the study drug. The anti -tumor response will 
be evaluated for up to [ADDRESS_436397] one dose of the study drug ALT -
801 will be included in the anti -tumor response evaluation.  Between each 
cohort and at the end of the study, all clinical and safety data will be analyzed for all patients enrolled in the study for dose- response effects.  
Population:  Patients of [ADDRESS_436398] an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 .  
Sample Size:  A total of up to 30 assessable  patients will be accrued to the initial dose 
escalation phase of the study (Phase Ib); the estimated number is 21.  Up to an additional 40 assessable patients will be enrolled at the expansion phase 
(Stage 1 and 2) of the study (Phase II) .  A total of approximately 60 
assessable patients will be enrolled and complete the study.  Assume a 20% ineligible or non - assessable cases, a total of up 72 patients may be accrued 
to the study. 
Primary  
Endpoints:  
For Stage I only:  (1) To define an MTD and RD for dose expansion of ALT -801 in 
combination with cisplatin and gemcitabine in the treatment of patients with muscle invasive or metastatic urothelial cancer.  
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: 05  
IND 100174                                           May 11, 2012  
Page 11 of 76 For Stage I & II:  (2) To assess the safety of the combi nation study treatment in treated 
patients.  
 (3) To assess the objective response rate in treated patients.  
Secondary  
Endpoints:  (1) To assess the progression free survival in treated patients.  
(2) To assess the overall survival in treated patients.  
(3) To evaluate the immunogenicity and pharmacokinetic profiles of ALT-
801 in treated patients. 
(4) To assess the relationship between tumor presentation of HLA -
A*0201/p53 aa 264-272 complexes and the safety and clinical benefit of study treatment.  
Pharmacokinetics  
& Bioma rkers:  Blood samples will be collected to assess typi[INVESTIGATOR_22588] -A2, immune cell 
levels, phenotype, pharmacokinetics, immunogenicity of the study drug 
ALT -801, and the serum levels of IFN -γ and TNF -α.  Tumor samples 
obtained from surgeries or biopsies perfo rmed prior to screening for the 
study will be collected to test the HLA -A*0201/p53 aa 264- [ADDRESS_436399] course of 
study treatment. Venous blood will be obtained at Time 0 (before the start of 
infusion), at 30 minutes (15 minutes after completion of infusion), and 1, [ADDRESS_436400] and second courses of study treatment.  HLA -A2 typi[INVESTIGATOR_351102]. 
Monitoring Tests:  Urine samples for urinalysis, blood samples for standard chemistry, CBC, diffe rential and coagulation will be obtained at screening, on each study drug 
infusion day, discharge days and follow -up visits.  Blood samples for 
immunogenicity testing, which include assays for anti- ALT -[ADDRESS_436401] ALT -
801 infusion day and at Week 9 from the initial dose of study treatment.  
Anti -tumor  
Response  
Evaluation: The anti -tumor response will be evaluated for up to 18 weeks from the initial 
dose of study treatment: for non -responders: Week 9 and 13; for early 
responders: Week 9 and 14; for late responders: Week 9, 13 and 18. 
Objective Response will be evaluated using the new international criteria 
proposed by [CONTACT_351121] (RECIST) 1. 1.  Baseline evaluations should be performed up to 28 days 
before starting study treatment. The same method of assessment and the 
CA-ALT -801-01-10    CONFIDENTIAL                       Version#: [ADDRESS_436402] of the treatment.  However, 
cystoscopic evaluation may be used routinely in this population, in addition to radiologic testing.  If surgeries or biopsies are performed after patients receive and respond to study treatment, tumor or tissue samples from these procedures will be collected to assess histopathological and immuno- cellular 
responses to study treatment. 
 Survival  
Assessment:  Progression- free survival and overall survival of all enrolled patients will be 
assessed at 6, 9, 12, 18, 24, 30 and 36 months from the start of study 
treatment, or through the point designated as the end of the study follow up. 
Adverse Events:  All p
 atients will be monitored and evaluated for clinical toxicities during the 
treatment period and queried at each follow -up visit for Adverse Events 
(AEs).  Patients may volunteer information concerning AEs.  All adverse events will be graded by [CONTACT_351117] 4.0 (CTCAE v4.0), and logged in the patient Case Report Form.  The study centers should report all SAEs and all events that trigger patient’s study treatment discontinuation to the sponsor via phone, fax or email (or a combination) up to 1 day after learning of the event.  The sponsor will use the information to manage and coordinate the dose escalation, cohort expansion and patient enrollment.  The sponsor will then inform all of the participating clinical sites of the current dose level and the number of patients to be enrolled at that level, or of any patient enrollment suspension via phone, fax or email within a day of its learning of the event.  The study centers should report the other adverse events to the sponsor following the guidelines defined in the study protocol. All study drug related adverse events (AEs) that are both serious and unexpected will be reported 
to the FDA in an expedited manner in accordance with 21 CFR §312.32. 
Statistical Plan:  For  each cohort, all AEs will be tabulated and examined and all safety and 
pharmacokinetic data will be evaluated. For estimation of duration of 
response, the Kaplan- Meier method will be used. P -values of < 0.05 (two-
sided) will be considered to indicate statistical significance.   
 
CA-ALT -801-01-10 CONFIDENTIAL                              Version#: 05  
IND 100174                                                            May 11, 2012  
Page 47 of 76 8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS 
8.1 Study calendar  
TESTS & PROCEDURES  SCREEN1 INITIAL TREATMENT PE RIOD  SCAN #1  SCAN #2  REPEAT 
TREATMENT  SCAN #3  FOLLOW -UPS  
COURSE 1  COURSE 2  COURSE 3  
Month (late responders in parentheses)   1 2 3 4 3 – 4/(4-5) 4/(5)  
  
  
  6 
  
  9 12 18 24 30 36 
Week (late responders in parentheses)   1 2 3 4 5 6 7 8 9 13 10/ 
(14) 11/ 
(15) 12/ 
(16) 13/ 
(17) 14/ 
(18)        
Week Day   M W F  M F  M W F M F  M W F M F     M M  M  M         
Treatment Day   1 3 5 8 12  22 24 26 29 33  43 45 47 50 54                     
Informed consent   X       
R 
e 
s 
t 
 
P 
e 
r 
i 
o 
d 
       
R 
e 
s 
t 
 
P 
e r 
i 
o 
d 
                    
Medical history  X                              
Serum pregnancy test2 X                              
Complete physical exam  X X     X     X     X X X      X        
Vital signs, weight, Height3 X X X X X X X X X X X X X X X X X X X X X X X        
Concurrent medication  X X X X X X X X X X X X X X X X X X X X X X X        
CBC with Differential, Blood Chemistry  X X X X X X X X X X X X X X X X X X X X X X X        
Coagulation (PT/INR)4 X                              
Urinalysis  X X      X     X       X            
Cardiac functions5 X X5 X X X X X5 X X X X X5 X X X X     X5 X X X         
Pulmonary functions  X                              
Adverse event assessment6 X X X X  X X X X X X X X X X X X X X X X X X X        
Tumor assessment7 X                   X X     X        
Survival Assessment8                          X X X X X X X 
HLA A2 Typi[INVESTIGATOR_007],  immune cell levels & phenotype11   X9      X9                       
HLA -A*0201/p53 tumor typi[INVESTIGATOR_007]    X                            
PK, IFNγ, TNFα11   X10                              
Immunogenicity tests11   X12               X                    
Cisplatin   c1     c2     c3                   
Gemcitabine   g1   g2  g3   g4  g5   g6                
Study drug (ALT -801)13    a1 a2 a3 a414   a5 a6 a7 a814   a9 a10 a11 a1214     a13 a14 a15 a16         
1Screening evaluations are performed < 14 days , scan/x -ray < 28 days  prior to start of therapy.  If the patient's condition is deteriorating, ECOG status and laboratory evaluations should be repeated within [ADDRESS_436403] is for women with childbearing potential only.  3Vital signs (especially blood pressure), clinical status and labora tory tests should be reviewed before start of therapy. Vital signs will be 
evaluated every 2 hours after the drug treatment and before discharge, and body weight before study treatment infusion on stu dy treatment infusion day. 4PT/INR  should be performed for any bleeding issues.  5Patients are closely 
monitored for hypotension, arrhythmia, angina and myocardial infarction. At screening, patients who are ≥ [ADDRESS_436404] 
(stress thallium, stress MUGA or dobutamine echocardiogram) to determine their eligibility for participation in the study. EKG will be performed for all patients at start of each treatment course and the repeat study drug treatment 
cours e. At the start of 1st course, EKG is performed only when >[ADDRESS_436405] an on -going study drug -related SAE upon study completion or at discontinuation of the study will be contact[CONTACT_351122]/her designee ever y week until the event is resolved or determined to be irreversible. 7Tumor response and progression will be evaluated in this study using the new international criteria proposed by [CONTACT_39694] (1.1). 
8Information about tumor assessment & other therapi[INVESTIGATOR_351104]  9Fresh blood samples for HLA A2 blood typi[INVESTIGATOR_007], immune cell levels & phenotype  testing will be 
collected before dosing. 10Collec t blood samples at Time 0 (before drug infusion), at 30 min (15 min after completion of infusion, +/ - 5 min), 1 hour (+/ - 10 min), 3 hour (+/ - 30 min), 6 hour (+/ - 60 min) from Time 0. IFN γ and 
TNFα assays are performed using the same samples and at the sa me schedule as PK .  11Residual samples may be used by [CONTACT_351118]. 12Use the same blood sample collected before dosing for 
PK test.13On the days when gemcitabine and ALT -[ADDRESS_436406].  14This dose can be delayed to the following Monday.   
 
 
 
CLINICAL STUDY PROTOCOL  
 
 
Protocol Number:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
 
  
Date of Protocol:   
Version # 01  
Version # 02 
Version # 03 Version # 04 Version # 05 Version # [ADDRESS_436407]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 
   
   INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
  
Date of Protocol:   
Version # 01  
Version # 02 
Version  # 03 
Version # 04 Version # 05 Version # [ADDRESS_436408]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by [CONTACT_22138], instructions, and restrictions contained in the attached protocol. 
 
Additionally, I will not initiate this study without approval of the appropriate Institutional 
Review Board (IRB), and I understand that any changes in the protocol must be approved in writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to subjects.  
  
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    
   
   
   
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 06 
IND 100174    October 18, 2012  
 
Page 3 of 82 
 Table of Contents 
SYNOPSIS  .............................................................................................................................................. 7 
1. OBJECTIVES .............................................................................................................................. 14 
1.1 P RIMARY OBJECTIVES  ............................................................................................................. 14 
1.2 S ECONDARY OBJECTIVES  ........................................................................................................ 14 
2. BACKGROUND .......................................................................................................................... 14 
2.1 ALT -801  – GENERAL INFORMATION  ...................................................................................... 14 
2.2 B LADDER CANCER  .................................................................................................................. 14 
2.3 I MMUNOTHERAPY  ................................................................................................................... 15 
2.4 I NTRATUMORAL TARGETIN G AND P 53 AS A TARGET FOR BIO THERAPY  .................................... 15 
2.5 P53 AS A THERAPEUTIC TA RGET FOR BLADDER CAN CER .......................................................... 17 
2.6 IN VITRO CHARACTERIZATION AND TUMOR EFFICACY STUDIES IN ANIMAL MODELS  ................. 17 
2.6.1 Efficacy evaluation of ALT -801 dose regimens in xenograft tumor models ..................... 18 
2.6.2 Efficacy of ALT -801 and non-targeted scTCR/IL-[ADDRESS_436409] UROTHELIAL CARCINOMA IN HUMANS & ANIMAL 
MODELS ............................................................................................................................................... 26 
3.2 ALT -801  IN COMBINATION WITH CHEMOTHERAPY AGAINS T UROTHELIAL CARCINO MA: ......... 28 
3.2.1 Myeloid-Derived Suppressive Cells in Patients with Bladder Cancer ............................. 29 
3.2.2 Enhancement of ALT -801 Anti -Tumor Immune Responses by [CONTACT_351123] .................... 29 
4. OVERALL STUDY DESIGN ..................................................................................................... 30 
5. STUDY POPULATION .............................................................................................................. 33 
5.1 I NCLUSION CRITERIA ............................................................................................................... 33 
5.2 E XCLUSION CRITERIA  ............................................................................................................. 34 
5.3 I NCLUSION OF WOMEN AND MINORITIES  .................................................................................. 34 
6. STUDY DESIGN ......................................................................................................................... 35 
6.1 S TUDY FLOW DIAGRAM  ........................................................................................................... 35 
6.2 S CREENING AND ENROLLM ENT ............................................................................................... 35 
6.3 S TUDY TREATMENT  ................................................................................................................ 35 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: [ADDRESS_436410]-therapy interventions ..................................................................... 37 
6.3.4 Study drug preparation and administration ...................................................................... 39 
[IP_ADDRESS] ALT -801 ................................................................................................................... 39 
[IP_ADDRESS] Cisplatin  .................................................................................................................... 39 
[IP_ADDRESS] Gemcitabine  .............................................................................................................. [ADDRESS_436411] ................................................................................................................. 40 
6.7 S TOPPI[INVESTIGATOR_16442]  ..................................................................................................................... 41 
6.8 P ATIENT MONITORING , ANTI-TUMOR RESPONSE EVALU ATION , SURVIVAL ASSESSMENT  ........... 41 
6.8.1 Patient monitoring ............................................................................................................ 41 
6.8.2 Anti-tumor response evaluation ........................................................................................ 42 
6.8.3 Survival assessment  ........................................................................................................... 42 
6.9 D OSE LIMITING TOXICITIES  ..................................................................................................... 42 
6.10 S TUDY TREATMENT DISCO NTINUATION  ................................................................................... 43 
6.10.1 Study treatment discontinuation events......................................................................... 43 
6.10.2 Follow-ups after treatment discontinuation .................................................................. 43 
[IP_ADDRESS]. Discontinuation due to SAEs or on-going study drug related AEs ...................... 43 
[IP_ADDRESS]. Discontinuation due to any other reasons ............................................................. 43 
6.10.3 Patient replacement  ...................................................................................................... 43 
6.11 S TUDY TREATMENT ADJUS TMENT  ........................................................................................... 44 
6.11.1 Kidney dysfunction ........................................................................................................ 44 
[IP_ADDRESS]. On days planned study treatment includes cisplatin ............................................. 44 
[IP_ADDRESS]. On days planned study treatment includes gemcitabine and/or ALT-801............ 44  
[IP_ADDRESS]. I nt
erventions ......................................................................................................... 44 
6.11.2 Hematological dysfunction ........................................................................................... 45 
[IP_ADDRESS]. On first dosing day of each study treatment week ................................................ 45 [IP_ADDRESS]. On intra-week dosing days ................................................................................... 45 
[IP_ADDRESS]. Transfusion and growth factor interventions ........................................................ 46 
6.11.3 Hypotension .................................................................................................................. 46 
6.11.4 Allergic reactions and cytokine release syndrome/acute infusion reaction.................. [ADDRESS_436412] UG INTERACTION  ........................................ 47 
6.14.1 ALT-801 ........................................................................................................................ 47 
[IP_ADDRESS]. Hypotension and capi[INVESTIGATOR_12737] ............................................................ 47 
[IP_ADDRESS]. Pulmonary dysfunction ......................................................................................... 48 
[IP_ADDRESS]. Impaired kidney and liver functions ..................................................................... 48 
[IP_ADDRESS]. Infection ................................................................................................................ 48 
[IP_ADDRESS]. Fever and chills ..................................................................................................... 48 
[IP_ADDRESS]. Gastritis  ................................................................................................................. 48 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 06 
IND 100174    October 18, 2012  
 
Page 5 of 82 
 [IP_ADDRESS]. Diarrhea, nausea and vomiting ............................................................................. 48 
[IP_ADDRESS]. Pruritus and dermatitis .......................................................................................... 48 
[IP_ADDRESS]. Acidosis ................................................................................................................ 49 
[IP_ADDRESS]. Life-threatening toxicities ..................................................................................... 49 
[IP_ADDRESS]. Other supportive care ............................................................................................ 49 
[IP_ADDRESS]. Drug interaction .................................................................................................... 49 
6.14.2 Cisplatin ........................................................................................................................ 50 
6.14.3 Gemcitabine  .................................................................................................................. 50 
7. STUDY DRUG: AVAILABILITY, ACCOUNTABILITY, PACK AGING & LABELING. 51 
7.1 ALT -801 ................................................................................................................................ 51 
7.1.1 Availability ........................................................................................................................ 51 
7.1.2 Accountability  ................................................................................................................... 51 
7.1.3 Packaging .......................................................................................................................... 51 
7.1.4 Labeling ............................................................................................................................ 51 
7.2 C ISPLATIN AND GEMCITABINE  ................................................................................................ 51 
8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS .............................................. 52 
8.1 S TUDY CALENDAR  .................................................................................................................. 52 
8.2 P ROCEDURE AND TESTS  .......................................................................................................... 53 
8.2.1 HLA -A2 typi[INVESTIGATOR_351101] ................................... 53 
8.2.2 Presentation of HLA-A*0201/p53 aa264-[ADDRESS_436413] ................................................................................................................... 53 
8.2.5 Physical examination ........................................................................................................ 53 
8.2.6 Vital signs, body weight & height ..................................................................................... 53 
8.2.7 Cardiac assessment ........................................................................................................... 53 
8.2.8 Blood tests ......................................................................................................................... 54 
8.2.9 Urinalysis  .......................................................................................................................... 54  
8.2.10  P
ulmonary functions  ..................................................................................................... 54 
8.2.11 Adverse event assessment  ............................................................................................. 54 
8.2.12 Tumor assessment  ......................................................................................................... 54 
8.2.13 Survival assessment  ...................................................................................................... 55 
8.2.14 Pharmacokinetic (PK) testing ....................................................................................... 55 
8.2.15 B
iomarker assays for IFN  and TNF  ....................................................................... [ADDRESS_436414] overall response  .................................................................................. 59 
9.4 C ONFIRMATORY  ..................................................................................................................... 59 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: [ADDRESS_436415] ING, REPORTING AND COMMUNICATION  ......................................... 62 
11.2 A DVERSE EVENT TERMINO LOGY AND DEFINITIONS  ................................................................. 62 
11.3 A DVERSE EVENT REPORTING PROCEDURES  ............................................................................ 63 
11.4 A DVERSE EVENT EXPEDITED REPORTING GUIDELINES  ........................................................... 64 
11.5 S UBMISSION OF SERIOUS  ADVERSE EVENT REPOR TING ............................................................ 64 
11.6 D ATA REPORTING FORMS  ....................................................................................................... 65 
11.7 R EPORT /DATA SUBMISSION ADDRE SS & CONTACT  ................................................................. 65 
11.8 P ATIENT RECORDS , QUALITY ASSURANCE , RECORDS RETENTION  ............................................. 66 
11.9 M ETHOD OF REVIEW  ............................................................................................................... 66 
11.10 S PECIAL REGULATORY CO NSIDERATIONS  ............................................................................ 66 
11.10.1 HIPAA  ........................................................................................................................... 66 
11.10.2 Protocol amendments, informed consent, and IRB approval ....................................... 67 
12. CONFIDENTIALITY  ............................................................................................................. 67 
13. ETHICAL STANDARDS & INVESTIGATOR OBLIGATIONS ..................................... [ADDRESS_436416] OF EXPECTED ADVERSE EVENTS ........................................................................ 68 
15. CTCAE  ..................................................................................................................................... 70  
REF
ERENCES  ..................................................................................................................................... 71 
APPENDIX A: PERFORMANCE STATUS CRITERIA  ................................................................ 74 
APPENDIX B: NEW YORK  HEART ASSOCIATION CLASSIFICATION ............................... 74 
APPENDIX C: ETHICAL STANDARDS  ......................................................................................... 75 
APPENDIX D: INVESTIGATOR OBLIGATIONS  ........................................................................ 76 
APPENDIX E: CONTACT [CONTACT_351110] - ALTOR ..................................................................................... 80 
APPENDIX F: CONTACT [CONTACT_351110] – DATA SAFETY MONITORING BOARD (DSM B) ............ 81 
APPENDIX G: CONTACT [CONTACT_351110] - LABORATORIES  ................................................................... 81 
APPENDIX H: APPROVAL  PAGE  .................................................................................................. 82  
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 06 
IND 100174  October 18, 2012  
 
 
Page 7 of 82 SYNOPSIS  
Sponsor:  Altor Bioscience Corporation 
Protocol#: CA-ALT -801-01-10 
Study Drug Name:  [CONTACT_351126]:  ALT -801 (c264scTCR- IL2), recombinant humanized, soluble single -chain 
TCR -cytokine fusion protein; Cisplatin; Gemcitabine.  
Study Type:  Interventional 
Study Phase:  Ib/II 
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination with Cisplatin and 
gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer  
Objectives:    To determine the safety and tolerability of the novel combination of ALT -
801 (c264scTCR -IL2) wi th cisplatin and gemcitabine or the combination of 
ALT -801 with gemcitabine alone  in patients with muscle invasive or 
metastatic urothelial cancer of bladder, renal pelvis, ureters and urethra.   
To estimate the anti- tumor activity of ALT -801 in combination with 
cisplatin and gemcitabine or ALT -801 in combination with gemcitabine 
alone by [CONTACT_351111] -tumor response, progression free 
survival (assessed through the  end of the study), and overall survival 
(assessed through the end of the stud y) in treated patients.  
To characterize the immunogenicity and pharmacokinetic profile of ALT -
801 in combination with cisplatin and gemcitabine and the immunogenicity 
of ALT -801 in combination with gemcitabine alone in treated patients.  
To assess the relationship between tumor presentation of HLA -A*0201/p53 
aa 264 -272 complex and the safety and clinical benefit of study treatment. 
Study Design:  This is a Phase Ib/II, open- label, multi- center, competitive enrollment and 
dose- escalation study of ALT -[ADDRESS_436417] muscle invasive or me tastatic urothelial cancer of bladder, 
renal pelvis, ureters and urethra. The study will be conducted in conformity 
with Current Good Clinical Practices (cGCP).  
The study includes a dose escalation phase (Phase Ib), to determine the maximum tolerated dose  (MTD) and the recommended dose (RD) of ALT -
801, and a dose expansion phase (Phase II) with study treatment containing ALT -[ADDRESS_436418] level, to assess the effectiveness of study treatment  
The Phase Ib dose escalation study is conducted using traditional  (3+3) dose 
escalation rules. Patients enrolled in his phase will all receive the cisplatin -
containing study treatment (ALT -801, cisplatin and gemcitabine). 
In the Phase II expansion study, conducted with the study treatment containing ALT -[ADDRESS_436419] le vel, patients are enrolled into two treatment 
groups – Expansion Group 1, treated with a cisplatin containing regimen: 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 06 
IND 100174  October 18, 2012  
 
 
Page 8 of 82 ALT -801, cisplatin and gemcitabine; Expansion Group 2, for platinum -
refractory patients, treated with a non -cisplatin containing regimen: ALT-
801 and gemcitabine. The Group 1 expansion will be conducted using a 
modified Simon two -stage design (1, 2). The Group [ADDRESS_436420] single -stage design [1] . After completion of Stage 
I expansion with the Expansion Group 1, patients with disease refractory to 
platinum- based therapi[INVESTIGATOR_351105] 2 to 
receive the non -cisplatin -containing study treatment as a “second -line” 
regimen.  
 
 [2, 3]  In the dose escalation  phase of this study, there are five dose levels of 
ALT -801 (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg, 0.10 mg/kg and 0.12 
mg/kg) in addition to two de -escalation dose levels. The doses of cisplatin 
(70 mg/m2/dose) and gemcitabine (1000 mg/m2/dose) will be fixed  across all 
ALT -[ADDRESS_436421] (DSMB) and the principal 
investigators will meet to discuss whether to amend the protocol to expand the dose escalation phase to include additional ALT-801 dose levels.  
Treatments:  The planned initial on- study treatment will be for 3 courses of chemo-
immunotherapy. Each course consists of cisplatin (Day #1), gemcitabine (Day #1), ALT -801 (Day #3 & Day #5), gemcitabine (Day #8), ALT -801 
(Day #8 & Day #12 or #15), and a rest period (Days #13 (or #16) - #21). The alternative dosing day (Day #15) for the last dose (dose #4) of ALT -801 in 
each course is provided to allow sufficient recovery from transient study drug related toxicities. P atients  with disease refractory to platinum- based 
therapi[INVESTIGATOR_351106] 2 will receive 
gemcitabine without cisplatin on Day # [ADDRESS_436422] received a 
total of 12 doses of the study drug ALT -801; 3 doses of cisplatin (no dose of 
cisplatin for patients enrolled to the Expansion Group 2); and [ADDRESS_436423] maintenance study treatment with an additional 3 -week course of ALT -801 
and gemcitabine: Gemcitabine and ALT -801 on Day #1 and Day #15, ALT -
801 on Day #3 and Day #17, and a rest period (Day #4 to Day #14).  Treatment delays or dose modifications or omissions are addressed in the protocol. The treatment schedule is illustrated in the following schemas:  
  
   
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 06 
IND 100174  October 18, 2012  
 
 
Page 9 of 82 Initial Study Treatment: 
 
 
 
 
*not given to patients who are enrolled in the Expansion Group 2 with 
disease refractory  to platinum- based therapy . 
Maintenance Study Treatment:  
 
 
 
 
Enrolled patients will receive the study treatment at qualified cancer 
treatment centers with adequate diagnostic and treatment facilities to provide appropriate management of therapy and complications. ALT -801, cisplatin 
and gemcitabine will be administered by [CONTACT_351113] a central or peripheral vein under the supervision of a qualified physician experienced 
in the use of anti -cancer agents including aldesleukin (Proleukin
), cisplatin 
and gemcitabine. 
This is the schema for the dose levels during the dose -escalation phase of the 
study. The - 1 and - 2 dose levels of ALT -801 are included in case of DLT 
events in the initial dose level.  
Cohort  ALT -801 Dose (mg/kg)  Cisplatin  (mg/m2) Gemcitabine (mg/m2) 
-2 0.01 70 1000  
-1 0.02 70 1000  
1 (initial)  0.04 70 1000  
2 0.06 70 1000  
3 0.08 70 1000  
4 0.10 70 1000  
5 0.12 70 1000  
Dose Escalation:  In this phase of the study, a minimum of 3 patients will be enrolled at each 
dose level. All patients will be monitored for Dose Limiting Toxicity (DLT) for 8 weeks from the initial dose. If 0/[ADDRESS_436424] a DLT that is drug -related, that dose level will 
be designated as exceeding the maximum tolerated dose. If there are 3 patients in the dose level below this level, then additional patients (up to 6 total) will be enrolled at that dose level. When there is a dose level with 0 or  Course 1  Course 2  Course 3  
Treatment Day 1 3 5 8 12(15)  13(16) -21 22 24 26 29 33(36) 34(37)-42 43 45 47 50 54(57)  
Cisplatin  X*     
Rest 
Period  X*     
Rest 
Period  X*     
Gemcitabine  X   X  X   X  X   X  
ALT -[ADDRESS_436425] 
Period  X  
ALT -801 X X X X 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 06 
IND 100174  October 18, 2012  
 
 
Page 10 of 82 1 out of 6 patients with DLT, which is either the maximum planned dose 
level (level 5) or which is one level below a dose that was not tolerated, the dose that is the maximum tolerated dose (MTD)  will be considered defined. 
Further changes in the treatment plan may be considered by [CONTACT_351119].  
If more than two of six patients experience a DLT at the initial dose level 
(level 1), then the sponsor, the Data Safety Monitoring Board (DSMB)  and 
the principal investigators will meet to determine how to adjust the dose level of cisplatin, gemcitabine, and/or the study drug downward, or continue with the ( -1) and ( -2) cohorts, and to determine how to proceed with the 
study.  
At any time during the dose escalation phase of the study, whether or not the 
MTD or the maximum planned escalating dose level is reached, the dose escalation phase may be concluded due to favorable anti -tumor effect 
observed in the enrolled patients. The DSMB will recommend a dose level of ALT -801, the recommended dose (RD), for the dose expansion phase of 
the study. 
Dose limiting toxicity (DLT) is defined as any toxicity of grade 3 that does 
not resolve to Grade 1 or lower within 7 days and any toxicity of Grade 4 occurring during treatment courses with exceptions and details described in the study protocol. Patients experiencing a DLT should discontinue study 
treatment. Study treatment discontinuation due to adverse events experienced 
prior to study drug administration, disease progression or patient’s decision to withdraw from study treatmen t without occurrence of any study treatment 
discontinuation event will not necessarily define a DLT event. Study treatment discontinuation events are defined in the protocol.  
Dose Expansion : The Phase II dose expansion study, conducted with study treatment containing ALT -[ADDRESS_436426] level, patients are enrolled to two treatment 
groups – Expansion Group 1, treated with a cisplatin containing regimen: 
ALT -801, cisplatin and gemcitabine; Expansion Group 2, for platinum -
refractory patients, treated with a no n-cisplatin containing regimen: ALT -
801 and gemcitabine. Both objective response (OR) (defined as complete response (CR) + partial response (PR)) and clinical benefit (CB) (defined as CR, PR + stable disease (SD)) will be evaluated.  
The Group 1 expansion will be conducted using a modified Simon two- stage 
design (1, 2). [2, 3] Common set thresholds of lack of efficacy (OR rate 
(ORR) = 40%; CB rate (CBR) = 78%) and an efficacy level of interest (ORR = 60%; CBR = 92%) will be selected.  The sample size was driven by t he 
parameter that had the larger sample size for each stage.  The Group [ADDRESS_436427] single- stage design [1]. 
Sample size for the expansion was calculated according to the single- stage 
design of A’Hern [1] to reject a baseline ORR of 10% when the true ORR is 
40%. 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 06 
IND 100174  October 18, 2012  
 
 
Page 11 of 82 Stoppi[INVESTIGATOR_1869]:  The patient enrollment will be temporarily suspended based on occurrence 
of any of the following, and the sponsor, the Data Safety Monitoring Board and principal investigators will meet to discuss h ow to proceed with future 
patient enrollment in the study:  
• If at any time during the dose escalation phase of the study,  
 more than one patient in a cohort of three, or two patients in a cohort of six patients experience any DLT or,  
 favorable anti -tumor re sponse data collected from enrolled patients 
that indicates a dose level with significant therapeutic effect may have been found 
• If at any time during the expansion phase of the study, more than 33% the patients experience any drug related DLT.  
Evaluations: Patients will be evaluated for clinical toxicities during the treatment. Patients’ blood samples will be collected to assess the pharmacokinetic profile and immunogenicity of the study drug. The anti -tumor response will 
be evaluated for up to [ADDRESS_436428] one dose of the study drug ALT -
801 will be included in the anti -tumor response evaluation. Between each 
cohort and at the end of the study, all clinical and safety data  will be 
analyzed for all patients enrolled in the study for dose- response effects.  
Population:  Patients of [ADDRESS_436429] an Eastern Cooperative Oncolog y Group (ECOG) performance 
status of 0 or 1.  
Sample Size:  A total of up to 30  assessable  patients will be accrued to the initial dose 
escalation phase of the study (Phase Ib); the estimated number is 9. In the dose expansion phase, up to an additional 40 assessable patients will be enrolled to 
receive cisplatin -containing study treatment in the Expansion Group 1  and 
up to 14 patients will be enrolled to receive non- cisplatin -containing study 
treatment in the Expansion Group 2. A total of approximately 63 assessable 
patients will be enrolled and complete the study. Assuming a 20% ineligible or non- assessable cases, a total of up to 76 patients may be accrued to the 
study.  
Primary  
Endpoints:  
For Stage I only:  (1) To define an MTD and/or RD for dose expansion of ALT -801 in 
combination with cisplatin and gemcitabine or ALT -801 in combination 
with gemcitabine alone in the treatment of patients with muscle invasive 
or metastatic urothelial cancer.  
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 06 
IND 100174  October 18, 2012  
 
 
Page 12 of 82 For Stage I & II:  (2) To assess the safety of the combination study treatment in treated 
patients.  
 (3) To assess the objective response rate in treated patients.  
Secondary  
Endpoints:  (1) To assess the progression free survival in treated patients.  
(2) To assess the overall survival in treated patients.  
(3) To evaluate the immunogenicity and pharmacokinetic profiles of ALT -
801 in treated patients. 
(4) To assess the relationship between tumor presentation of HLA -
A*0201/p53 aa264 -272 complexes and the safety and clinical benefit of 
study treatment.  
Pharmacokinetics  
& Biomarkers:  B lood samples will be collected to assess typi[INVESTIGATOR_22588] -A2, immune cell 
levels, phenotype, pharmacokinetics, immunogenicity of the study drug 
ALT -801, and the serum levels of IFN -γ and TNF -α. Tumor samples 
obtained from surgeries or biopsies performed prior to screening for the 
study will be collected to test the HLA -A*0201/p53 aa 264- [ADDRESS_436430] course of 
study treatment. Venous blood will be obtained at Time 0 (before the start of infusion), at 30 minutes (15 minutes after completion of infusion), and 1, [ADDRESS_436431] and second courses of study treatment. HLA -A2 typi[INVESTIGATOR_351102]. 
Monitoring Tests:  Urine samples for urinalysis, blood samples for standard chemistry, CBC, differential and coagulation will be obtained for tests required at screening for study entry eligibility evaluation or for tests required throughout the treatment and follow -up periods for patient safety monitoring. Blood 
samples for immunogenicity testing, which include assays for anti- ALT -[ADDRESS_436432] 
ALT -801 infusion day and at Week 9 from the initial dose of s tudy 
treatment.  
Anti -tumor  
Response  
Evaluation: The anti -tumor response will be evaluated for up to 18 weeks from the initial 
dose of study treatment: for non -responders: Week 9 and 13; for early 
responders: Week 9 and 14; for late responders: Week 9, 13 and 18. 
Objective Response will be evaluated using the new international criteria 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 06 
IND 100174  October 18, 2012  
 
 
Page 13 of 82 proposed by [CONTACT_351121] 
(RECIST) 1.1. Baseline evaluations should be performed up to [ADDRESS_436433] of the treatment. However, 
cystoscopic evaluation may be used routinely in this population, in addition to radiologic testing. If surgeries or biopsies are performed after patients receive and respond to study treatment, tumor or tissue samples from these procedures will be collected to assess histopathological and immuno- cellular 
responses to study treatment. 
 Survival  
Assessment:  Progression- free survival and overall survival of all enrolled patients will be 
assessed at 6, 9, 12, 18, 24, 30 and 36 months from the start of study 
treatment, or through the point designated as the end of the study follow up. 
Adverse Events:  All p
 atients will be monitored and evaluated for clinical toxicities during the 
treatment p eriod and queried at each follow -up visit for Adverse Events 
(AEs). Patients may volunteer information concerning AEs. All adverse events will be graded by [CONTACT_351117] 4.0 (CTCAE v4.0), and logged in the patient Case 
Report Form. The study centers should report all SAEs and all events that trigger patient’s study treatment discontinuation to the sponsor via phone, fax or email (or a combination) up to 1 day after learning of the event. The sponsor will use the information to manage and coordinate the dose escalation, cohort expansion and patient enrollment. The sponsor will then inform all of the participating clinical sites of the current dose level and the number of patients to be enrolled at that le vel, or of any patient enrollment 
suspension via phone, fax or email within a day of its learning of the event. The study centers should report the other adverse events to the sponsor following the guidelines defined in the study protocol. All study drug r elated 
adverse events (AEs) that are both serious and unexpected will be reported 
to the FDA in an expedited manner in accordance with 21 CFR §312.32. 
Statistical Plan:  For  each cohort, all AEs will be tabulated and examined and all safety and 
pharmacokine tic data will be evaluated. For estimation of duration of 
response, the Kaplan- Meier method will be used. P -values of < 0.05 (two-
sided) will be considered to indicate statistical significance.  
 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 06 
IND 100174  October 18, 2012  
 
 
Page 52 of 82 8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS 
8.1 Study calendar  
TESTS & PROCEDURES  SCREEN1 INITIAL TREATMENT PE RIOD  SCAN #1  SCAN #2  MAINTENANCE 
TREATMENT  SCAN #3  FOLLOW -UPS  
COURSE 1  COURSE 2 COURSE 3  
Month (late responders in parentheses)   1 2 3 4 3 – 4/(4-5) 4/(5)  
  
  
  6 
  
  9 12 18 24 30 36 
Week (late responders in parentheses)   1 2 3 4 5 6 7 8 9 13 10/ 
(14) 11/ 
(15) 12/ 
(16) 13/ 
(17)        
Week Day   M W F  M F  M W F M F  M W F M F     M W   M  W         
Treatment Day   1 3 5 8 12  22 24 26 29 33  43 45 47 50 54      1 3   15   17         
Informed consent   X       
R 
e 
s 
t 
 
P 
e 
r 
i 
o 
d 
       
R 
e 
s 
t 
 
P 
e r 
i 
o 
d 
           
R 
e 
s 
t 
 
P 
e 
r 
i 
o 
d           
Medical history  X                              
Serum pregnancy test2 X                              
Complete physical exam  X X     X     X     X X X      X        
Vital signs, weight, Height3 X X X X X X X X X X X X X X X X X X X X X X X        
Concurrent medication  X X X X X X X X X X X X X X X X X X X X X X X        
CBC with Differential, Blood Chemistry  X X X X X X X X X X X X X X X X X X X X X X X        
Coagulation (PT/INR)4 X                              
Urinalysis  X X      X     X       X            
Cardiac functions5 X X5 X X X X X5 X X X X X5 X X X X     X5 X X X         
Pulmonary functions  X                              
Adverse event assessment6 X X X X  X X X X X X X X X X X X X X X X X X X        
Tumor assessment7 X                   X X     X        
Survival Assessment8                          X X X X X X X 
HLA A2 Typi[INVESTIGATOR_007],  immune cell levels & 
phenotype11  X9 X9  X9    X9                       
HLA -A*0201/p53 tumor typi[INVESTIGATOR_007]    X                            
PK, IFNγ, TNFα11   X10                              
Immunogenicity tests11   X12               X                    
Cisplatin   c1     c2     c3                   
Gemcitabine   g1   g2  g3   g4  g5   g6    g7  g8          
Study drug (ALT -801)13    a1 a2 a3 a414   a5 a6 a7 a814   a9 a10 a11 a1214     a13 a14 a15 a16         
1Screening evaluations are performed < 14 days;  stress test, if required, scan/x -ray <28 days  prior to start of therapy.  If the patient's condition is deteriorating, ECOG status and laboratory evaluations should be repeated within [ADDRESS_436434] is for women with childbearing potential only.  3Vital signs (especially blood pressure), clinical status and laboratory tests should be reviewed before start of 
therapy. Vital signs will be evaluated every 2 hours after the drug treatment and before discharge, and body weight before study treatment infusion on study treatment infusion day. 4PT/INR should be performed for any bleeding 
issues. 5Patients are closely monitored for hypotension, arrhythmia, angina and myocardial infarction. At screening, pati ents who are ≥ [ADDRESS_436435] (stress thallium, stress MUGA or dobutamine echocardiogram) to determine their eligibility  for participation in the study. EKG will be performed for all patients at start of each initial treatment 
course and the maintenance study  treatment course. At the start of 1st course, EKG is performed only when >[ADDRESS_436436] an on -going study drug -related SAE upon study completion or at 
discontinuation of the study will be contact[CONTACT_33981]/her designee every week until the event is resolved  or determined to be irreversible. 7Tumor response and progression will be evaluated in this st udy using the 
new international criteria proposed by [CONTACT_39694] (1.1). 8Information about tumor assessment & other therapi[INVESTIGATOR_351107]   9Fresh blood samples for HLA A2 blood 
typi[INVESTIGATOR_007], immune cell levels & phenotype  testing will be collected before dosing. 10Collect blood samples at Time 0 (before drug infusion), at 30 min (15 min after completion of infusion, +/ - 5 min), 1 hour (+/ - 10 min), 3 hour (+/ - 30 
min), 6 hour (+/ - 60 min) from Time [ADDRESS_436437].  14This dose can be delayed to the 
following Monday.  
 
 
 
CLINICAL STUDY PROTOCOL  
 
 
Protocol Number:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib /II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
 
  
Date of Protocol:   
Version # 01  
Version # 02 
Version # 03 Version # 04 Version # 05 Version # 06 Version # [ADDRESS_436438]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 
 
INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -801-01-10 
  
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination 
with Cisplatin and Gemcitabine in Muscle 
Invasive or Metastatic Urothelial Cancer  
  
Date of Protocol:   
Version # 01  
Version # 02 
Version # 03 Version # 04 Version # 05 Version # 06 Version # [ADDRESS_436439]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261]  
  
 By [CONTACT_12006], I hereby [CONTACT_22052] I have read,  and that I understand and will abide by [CONTACT_141515], instructions, and restrictions contained in the attached protocol. 
 
Additionally, I will not initiate this study without approval of the appropriate Institutional Review 
Board (IRB), and I understand that any changes in the protocol must be approved in writing by [CONTACT_103], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to subjects.  
  
   
Principal Investigator’s Signatur e  Date  
   
   
   
Principal Investigator’s Name (Print)    
   
 
  
   
   
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 07 
IND 100174    March 29, 2013  
 
Page 3 of 82 
 Table of Contents 
SYNOPSIS  .............................................................................................................................................. 7 
1. OBJECTIVES .............................................................................................................................. 14 
1.1 P RIMARY OBJECTIVES  ............................................................................................................. 14 
1.2 S ECONDARY OBJECTIVES  ........................................................................................................ 14 
2. BACKGROUND .......................................................................................................................... 14 
2.1 ALT -801  – GENERAL INFORMATION  ...................................................................................... 14 
2.2 B LADDER CANCER  .................................................................................................................. 14 
2.3 I MMUNOTHERAPY  ................................................................................................................... 15 
2.4 I NTRATUMORAL TARGETIN G AND P 53 AS A TARGET FOR BIO THERAPY  .................................... 15 
2.5 P53 AS A THERAPEUTIC TA RGET FOR BLADDER CAN CER .......................................................... 17 
2.6 IN VITRO CHARACTERIZATION AND TUMOR EFFICACY STUDIES IN ANIMAL MODELS  ................. 17 
2.6.1 Efficacy evaluation of ALT-801 dose regimens in xenograft tumor models ..................... 18 
2.6.2 Efficacy of ALT -801 and non-targeted scTCR/IL-[ADDRESS_436440] UROTHELIAL CARCINOMA IN HUMANS & ANIMAL 
MODELS ............................................................................................................................................... 26 
3.2 ALT -801  IN COMBINATION WITH CHEMOTHERAPY AGAINS T UROTHELIAL CARCINO MA: ......... 28 
3.2.1 Myeloid-Derived Suppressive Cells in Patients with Bladder Cancer ............................. 29 
3.2.2 Enhancement of ALT -801 Anti -Tumor Immune Responses by [CONTACT_351123] .................... 30 
4. OVERALL STUDY DESIGN ..................................................................................................... 30 
5. STUDY POPULATION .............................................................................................................. 33 
5.1 I NCLUSION CRITERIA ............................................................................................................... 33 
5.2 E XCLUSION CRITERIA  ............................................................................................................. 34 
5.3 I NCLUSION OF WOMEN AND MINORITIES  .................................................................................. 34 
6. STUDY DESIGN ......................................................................................................................... 35 
6.1 S TUDY FLOW DIAGRAM  ........................................................................................................... 35 
6.2 S CREENING AND ENROLLM ENT ............................................................................................... 35 
6.3 S TUDY TREATMENT  ................................................................................................................ 35 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: [ADDRESS_436441]-therapy interventions ..................................................................... 37 
6.3.4 Study drug preparation and administration ...................................................................... 39 
[IP_ADDRESS] ALT -801 ................................................................................................................... 39 
[IP_ADDRESS] Cisplatin  .................................................................................................................... 39 
[IP_ADDRESS] Gemcitabine  .............................................................................................................. [ADDRESS_436442] ................................................................................................................. 40 
6.7 S TOPPI[INVESTIGATOR_16442]  ..................................................................................................................... 41 
6.8 P ATIENT MONITORING , ANTI-TUMOR RESPONSE EVALU ATION , SURVIVAL ASSESSMENT  ........... 42 
6.8.1 Patient monitoring ............................................................................................................ 42 
6.8.2 Anti-tumor response evaluation ........................................................................................ 42 
6.8.3 Survival assessment  ........................................................................................................... 42 
6.9 D OSE LIMITING TOXICITIES  ..................................................................................................... 42 
6.10 S TUDY TREATMENT DISCO NTINUATION  ................................................................................... 43 
6.10.1 Study treatment discontinuation events......................................................................... 43 
6.10.2 Follow-ups after treatment discontinuation .................................................................. 43 
[IP_ADDRESS]. Discontinuation due to SAEs or on-going study drug related AEs ...................... 43 
[IP_ADDRESS]. Discontinuation due to any other reasons ............................................................. 44 
6.10.3 Patient replacement  ...................................................................................................... 44 
6.11 S TUDY TREATMENT ADJUS TMENT  ........................................................................................... 44 
6.11.1 Kidney dysfunction ........................................................................................................ 44 
[IP_ADDRESS]. On days planned study treatment includes cisplatin ............................................. 44 
[IP_ADDRESS]. On days planned study treatment includes gemcitabine and/or ALT-801............ 45  
[IP_ADDRESS]. I nt
erventions ......................................................................................................... 45 
6.11.2 Hematological dysfunction ........................................................................................... 45 
[IP_ADDRESS]. On first dosing day of each study treatment week ................................................ 45 [IP_ADDRESS]. On intra-week dosing days ................................................................................... 46 
[IP_ADDRESS]. Transfusion and growth factor interventions ........................................................ 46 
6.11.3 Hypotension .................................................................................................................. 46 
6.11.4 Allergic reactions and cytokine release syndrome/acute infusion reaction.................. [ADDRESS_436443] UG INTERACTION  ........................................ 47 
6.14.1 ALT-801 ........................................................................................................................ 47 
[IP_ADDRESS]. Hypotension and capi[INVESTIGATOR_12737] ............................................................ 48 
[IP_ADDRESS]. Pulmonary dysfunction ......................................................................................... 48 
[IP_ADDRESS]. Impaired kidney and liver functions ..................................................................... 48 
[IP_ADDRESS]. Infection ................................................................................................................ 48 
[IP_ADDRESS]. Fever and chills ..................................................................................................... 48 
[IP_ADDRESS]. Gastritis  ................................................................................................................. 49 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 07 
IND 100174    March 29, 2013  
 
Page 5 of 82 
 [IP_ADDRESS]. Diarrhea, nausea and vomiting ............................................................................. 49 
[IP_ADDRESS]. Pruritus and dermatitis .......................................................................................... 49 
[IP_ADDRESS]. Acidosis ................................................................................................................ 49 
[IP_ADDRESS]. Life-threatening toxicities ..................................................................................... 49 
[IP_ADDRESS]. Other supportive care ............................................................................................ 49 
[IP_ADDRESS]. Drug interaction .................................................................................................... 49 
6.14.2 Cisplatin ........................................................................................................................ 50 
6.14.3 Gemcitabine  .................................................................................................................. 50 
7. STUDY DRUG: AVAILABILITY, ACCOUNTABILITY, PACK AGING & LABELING. 51 
7.1 ALT -801 ................................................................................................................................ 51 
7.1.1 Availability ........................................................................................................................ 51 
7.1.2 Accountability  ................................................................................................................... 51 
7.1.3 Packaging .......................................................................................................................... 51 
7.1.4 Labeling ............................................................................................................................ 51 
7.2 C ISPLATIN AND GEMCITABINE  ................................................................................................ 51 
8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS .............................................. 52 
8.1 S TUDY CALENDAR  .................................................................................................................. 52 
8.2 P ROCEDURE AND TESTS  .......................................................................................................... 53 
8.2.1 HLA -A2 typi[INVESTIGATOR_351101] ................................... 53 
8.2.2 Presentation of HLA-A*0201/p53 aa264-[ADDRESS_436444] ................................................................................................................... 53 
8.2.5 Physical examination ........................................................................................................ 53 
8.2.6 Vital signs, body weight & height ..................................................................................... 53 
8.2.7 Cardiac assessment ........................................................................................................... 53 
8.2.8 Blood tests ......................................................................................................................... 54 
8.2.9 Urinalysis  .......................................................................................................................... 54  
8.2.10  P
ulmonary functions  ..................................................................................................... 54 
8.2.11 Adverse event assessment  ............................................................................................. 54 
8.2.12 Tumor assessment  ......................................................................................................... 54 
8.2.13 Survival assessment  ...................................................................................................... 55 
8.2.14 Pharmacokinetic (PK) testing ....................................................................................... 55 
8.2.15 B
iomarker assays for IFN  and TNF  ....................................................................... [ADDRESS_436445] overall response  .................................................................................. 59 
9.4 C ONFIRMATORY  ..................................................................................................................... 59 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: [ADDRESS_436446] ING, REPORTING AND COMMUNICATION  ......................................... 62 
11.2 A DVERSE EVENT TERMINO LOGY AND DEFINITIONS  ................................................................. 62 
11.3 A DVERSE EVENT REPORTING PROCEDURES  ............................................................................ 63 
11.4 A DVERSE EVENT EXPEDITED REPORTING GUIDELINES  ........................................................... 64 
11.5 S UBMISSION OF SERIOUS  ADVERSE EVENT REPOR TING ............................................................ 64 
11.6 D ATA REPORTING FORMS  ....................................................................................................... 65 
11.7 R EPORT /DATA SUBMISSION ADDRE SS & CONTACT  ................................................................. 65 
11.8 P ATIENT RECORDS , QUALITY ASSURANCE , RECORDS RETENTION  ............................................. 66 
11.9 M ETHOD OF REVIEW  ............................................................................................................... 66 
11.10 S PECIAL REGULATORY CO NSIDERATIONS  ............................................................................ 66 
11.10.1 HIPAA  ........................................................................................................................... 66 
11.10.2 Protocol amendments, informed consent, and IRB approval ....................................... 67 
12. CONFIDENTIALITY  ............................................................................................................. 67 
13. ETHICAL STANDARDS & INVESTIGATOR OBLIGATIONS ..................................... [ADDRESS_436447] OF EXPECTED ADVERSE EVENTS ........................................................................ 68 
15. CTCAE  ..................................................................................................................................... 70 
REFERENCES  ..................................................................................................................................... 71 
APPENDIX A: PERFORMANCE STATUS CRITERI A ................................................................ 74 
APPENDIX B: NEW YORK  HEART ASSOCIATION CLASSIFICATION ............................... 74 
APPENDIX C: ETHICAL STANDARDS  ......................................................................................... 75 
APPENDIX D: INVESTIGATOR OBLIGATIONS  ........................................................................ 76 
APPENDIX E: CONTACT [CONTACT_351110] - ALTOR ..................................................................................... 80 
APPENDIX F: CONTACT [CONTACT_351110] – DATA SAFETY MONITORING BOARD (DSM B) ............ 81 
APPENDIX G: CONTACT [CONTACT_351110] - LABORATORIES  ................................................................... 81 
APPENDIX H: APPROVAL  PAGE  .................................................................................................. 82  
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 07 
IND 100174  March 29, 2013  
 
 
Page 7 of 82 SYNOPSIS  
Sponsor:  Altor Bioscience Corporation 
Protocol#: CA-ALT -801-01-10 
Study Drug Name:  [CONTACT_351126]:  ALT -801 (c264scTCR- IL2), recombinant humanized, soluble single -chain 
TCR -cytokine fusion protein; Cisplatin; Gemcitabine.  
Study Type:  Interventional 
Study Phase:  Ib/II 
Protocol Title:  A Phase Ib/II Trial of ALT -801 in Combination with Cisplatin and 
gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer  
Objectives:    To determine the safety and tolerability of the novel combination of ALT -
801 (c264scTCR -IL2) wi th cisplatin and gemcitabine or the combination of 
ALT -801 with gemcitabine alone  in patients with muscle invasive or 
metastatic urothelial cancer of bladder, renal pelvis, ureters and urethra.   
To estimate the anti- tumor activity of ALT -801 in combination with 
cisplatin and gemcitabine or ALT -801 in combination with gemcitabine 
alone by [CONTACT_351111] -tumor response, progression free 
survival (assessed through the  end of the study), and overall survival 
(assessed through the end of the stud y) in treated patients.  
To characterize the immunogenicity and pharmacokinetic profile of ALT -
801 in combination with cisplatin and gemcitabine and the immunogenicity 
of ALT -801 in combination with gemcitabine alone in treated patients.  
To assess the relationship between tumor presentation of HLA -A*0201/p53 
aa 264 -272 complex and the safety and clinical benefit of study treatment. 
Study Design:  This is a Phase Ib /II, open -label, multi- center, competitive enrollment and 
dose- escalation study of ALT -[ADDRESS_436448] muscle invasive or metastatic urothelial cancer of bladder, 
renal pelvis, ureters and urethra. The study will be conducted in conformity with Current Good Clinical Practices (cGCP).  
The study includes a dose escalation phase (Phase Ib), to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of ALT -
801, and a dose expansion phase (Phase II) with study treatment containing ALT -[ADDRESS_436449] level, to assess the effectiveness of study treatment  
The Phase Ib  dose escalation study is conducted using traditional (3+3) dose 
escalation rules. Patients enrolled in his phase will all receive the cisplatin -
containing study treatment (ALT -801, cisplatin and gemcitabine). 
The Phase II expansion study  is conducted with the study treatment 
containing ALT -[ADDRESS_436450] level .  Patients are enrolled into two 
treatment groups – Expansion Group 1, treated with a cisplatin-containing 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 07 
IND 100174  March 29, 2013  
 
 
Page 8 of 82 regimen  (ALT -801, cisplatin and gemcitabine ) and Expansion Group 2, for 
platinum- refractory p atients, consisting of two regimen arms based on the 
patient’s renal function . In this study, platinum -refractory is defined as 
disease progression while on prior platinum -based therapi[INVESTIGATOR_351108] [ADDRESS_436451] dose of a plat inum- based therapy.  
The Group 1 expansion will be conducted using a modified Simon two- stage 
design [2, 3] . The Group [ADDRESS_436452] 
single -stage design [1] . After completion of Stage I expansion with the 
Expansion Group 1, platinum- refractory patients  will be enrolled to the 
Expansion Group 2 to receive either the cisplatin -containing or non-
cisplatin -containing regimen  as a “second -line” therapy .  
In the dose escalation phase of this study, there are five dose levels of ALT -
801 (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg, 0.10 mg/kg and 0.12 mg/kg) in 
addition to two de -escalation dose levels. The doses of cisplatin (70 
mg/m2/dose) and gemcitabine (1000 mg/m2/dose) will be fixed across all 
ALT -[ADDRESS_436453] (DSMB) and the principal investigators will meet to discuss whether to amend the  protocol to expand 
the dose escalation phase to include additional ALT-801 dose levels.  
Treatments:  Each enrolled patient will receive up to two 3- course study treatments with a 
cisplatin -containing regimen or a non- cisplatin -containing regimen. Each 
treatment regimen consists of 3 courses of the following chemo-
immunotherapy: cisplatin (Day #1 , only for cisplatin- containing regimen ), 
gemcitabine (Day #1), ALT -801 (Day #3 & Day #5), gemcitabine (Day #8), 
ALT -801 (Day #8 & Day #12 or #15), and a rest period (Days #13 (or #16) - 
#21). The alternative dosing day (Day #15) for the last dose (dose #4) of ALT -[ADDRESS_436454] received a 
total of up to 12 doses of the study d rug ALT -801; 3 doses of cisplatin ( no 
doses of cisplatin for patients enrolled to the non- cisplatin -containing arm in  
Expansion Group 2); and [ADDRESS_436455] stable d isease and 
meet other treatment criteria will receive an additional 3 courses of chemo -
immunotherapy, during the maintenance treatment  period, at the same dose 
level and with the same dosing schedule as the initial treatment regimen . 
Treatment delays , dose modifications , or omissions are addressed in the 
protocol. The treatment schedule for a 3 -course study treatment regimen 
given during  the initial and maintenance treatment periods  is illustrated 
below: 
  
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 07 
IND 100174  March 29, 2013  
 
 
Page 9 of 82 3-Course Study Treatment:  
 
 
 
*not given to patients who are enrolled in the non- cisplatin -containing arm 
of Expansion Group 2. 
 
Enrolled patients will receive the study treatment at qualified cancer 
treatment centers with adequate diagnostic and treatment facilities to provide 
appropriate management  of therapy and complications. ALT -801, cisplatin 
and gemcitabine will be administered by [CONTACT_351113] a central or peripheral vein under the supervision of a qualified physician experienced 
in the use of anti -cancer agents including aldesleuk in (Proleukin
), cisplatin 
and gemcitabine. 
This is the schema for the dose levels during the dose -escalation phase of the 
study. The - 1 and - 2 dose levels of ALT -801 are included in case of DLT 
events in the initial dose level.  
Cohort  ALT -801 Dose (mg/kg)  Cisplatin  (mg/m2) Gemcitabine (mg/m2) 
-2 0.01 70 1000  
-1 0.02 70 1000  
1 (initial)  0.04 70 1000  
2 0.06 70 1000  
3 0.08 70 1000  
4 0.10 70 1000  
5 0.12 70 1000  
Dose Escalation:  In this phase of the study, a minimum of 3 patients will be enrolled at each 
dose level. All patients will be monitored for Dose Limiting Toxicity (DLT) for 8 weeks from the initial dose. If 0/[ADDRESS_436456] a DLT that is drug -related, that dose level will 
be designated as exceeding the maximum tolerated dose. If there are 3 patients in the dose level below this level, then additional patients (up to 6 total) will be enrolled at that dose level. When there is a dose level with 0 or 1 out of 6 patients with DLT, which is either the maximum planned dose level (level 5) or which is one level below a dose that was not tolerated, the dose that is the maximum tolerated dose (MTD)  will be considered defined. 
Further changes in the treatment plan may be considered by [CONTACT_351119].   Course 1  Course 2  Course 3  
Treatment Day 1 3 5 8 12(15)  13(16) -21 22 24 26 29 33(36) 34(37)- 42 43 45 47 50 54(57)  
Cisplatin  X*     
Rest 
Period  X*     
Rest 
Period  X*     
Gemcitabine  X   X  X   X  X   X  
ALT -801  X X X X  X X X X  X X X X 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 07 
IND 100174  March 29, 2013  
 
 
Page 10 of 82 If more than two of six patients experience a DLT at the initial dose level 
(level 1), then the sponsor, the Data Safety Monitoring Board (DSMB)  and 
the principal investigators will meet to determine how to adjust the dose level of cisplatin, gemcitabine, and/or the study drug downward, or continue with the ( -1) and ( -2) cohorts, and to determine how to proceed with the 
study.  
At any time during the dose escalation phase of the study, whether or not the 
MTD or the m aximum planned escalating dose level is reached, the dose 
escalation phase may be concluded due to favorable anti -tumor effect 
observed in the enrolled patients. The DSMB will recommend a dose level of ALT -801, the recommended dose (RD), for the dose expansion phase of 
the study. 
Dose limiting toxicity (DLT) is defined as any toxicity of grade 3 that does 
not resolve to Grade 1 or lower within 7 days and any toxicity of Grade 4 occurring during treatment courses with exceptions and details described in the study protocol. Patients experiencing a DLT should discontinue study 
treatment. Study treatment discontinuation due to adverse events experienced 
prior to study drug administration, disease progression or patient’s decision to withdraw from study treatment without occurrence of any study treatment 
discontinuation event will not necessarily define a DLT event. Study treatment discontinuation events are defined in the protocol.  
Dose Expansion : The Phase II dose expansion study, conducted with study treatment  
containing ALT -[ADDRESS_436457] level, patients are enrolled to two treatment 
groups – Expansion Group 1, treated with a cisplatin- containing regimen, 
and Expansion Group 2, for platinum -refractory patients, consist ing of two 
treatment arms based on the pati ent’s renal function. The cisplatin -
containing regimen  arm is for patients who have sufficient renal function. 
The non- cisplatin -containing regimen arm is for patients who do not have 
sufficient renal function for platinum- based therap ies. In this study, platinum 
refractory is defined as disease progression while on prior platinum -based 
therapi[INVESTIGATOR_351109] [ADDRESS_436458] dose of a 
platinum- based therapy.   Both objective response (OR) (defined as complete 
response (CR) + partial response (PR)) and clinical benefit (CB) (defined as CR, PR + stable disease (SD)) will be evaluated.  
Group 1 expansion will be conducted using a modified Simon two- stage 
design [2, 3] . The sample size was driven by [CONTACT_351124] [2, 3] . Common set thresholds of lack of 
efficacy (OR rate (ORR) = 40%; CB rate (CBR) = 78%) and an efficacy level of interest (ORR = 60%; CBR = 92%) will be selected.  For Group [ADDRESS_436459] single -
stage design [1]. Sample size for the expansion was calculated according to 
the single -stage design of A’Hern [1] to reject a baseline ORR of 10% when 
the true ORR is 40%. 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 07 
IND 100174  March 29, 2013  
 
 
Page 11 of 82 Stoppi[INVESTIGATOR_1869]:  The patient enrollment will be temporarily suspended based on occurrence 
of any of the following, and the sponsor, the Data Safety Monitoring Board and principal investigators will meet to discuss how to proceed with future patient enrollment in the study:  
If at any time during the dose es calation phase of the study,  
 more than one patient in a cohort of three, or two patients in a cohort of six patients experience any DLT or,  
 favorable anti -tumor response data collected from enrolled patients 
that indicates a dose level with significant th erapeutic effect may 
have been found 
If at any time during the expansion phase of the study,  
 more than 33% the patients experience any drug related DLT , 
 if favorable anti -tumor response data collected from patients 
enrolled in an expansion group demonstrates significant therapeutic effect  
Evaluations: Patients will be evaluated for clinical toxicities during the treatment. Patients’ blood samples will be collected to assess the pharmacokinetic profile and immunogenicity of the study drug. The anti -tumor response will 
be evaluated for up to [ADDRESS_436460] three doses  of the study drug 
ALT -801 will be included in the anti -tumor response evaluation. Between 
each cohort  and at the end of the study, all clinical and safety data will be 
analyzed for all patients enrolled in the study for dose- response effects.  
Population:  Patients of [ADDRESS_436461] an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.  
Sample Size:  A total of up to 30  assessable  patients will be accrued to the initial dose 
escalation phase of the study (Phase Ib); the estimated number is 9. In the dose expansion phase, up to an additional 40 assessable patients will be enrolled to 
receive cisplatin -containing study treatment in the Expansion Group 1 and 
up to 13 assessable patients will be enrolled to each of the two treatment arms in the Expansion Group 2. A total of approximately 75 assessable 
patients will be enrolled and complete the study. Assuming a 20% ineligible or non- assessable cases, a total of up to 90 patients may be accrued to the 
study.  
 
 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 07 
IND 100174  March 29, 2013  
 
 
Page 12 of 82 Primary  
Endpoints:  
For Stage I only:  (1) To define an MTD and/or RD for dose expansion of ALT -801 in 
combination with cisplatin and gemcitabine or ALT -801 in combination 
with gemcitabine alone in the treatment of patients with muscle invasive 
or metastatic urothelial cancer.  
For Stage I & II:  (2) To assess the safety of the combination study treatment in treated 
patients.  
 (3) To assess the objective response rate in treated patients.  
Secondary  
Endpoints:  (1) To assess the progression free survival in treated patients.  
(2) To assess the overall survival in treated patients.  
(3) To evaluate the immunogenicity and pharmacokinetic profiles of ALT -
801 in treated patients. 
(4) To assess the relationship between tumor presentation of HLA -
A*0201/p53 aa264 -272 complexes and the safety and clinical benefi t of 
study treatment.  
Pharmacokinetics  
& Biomarkers:  Blood samples will be collected to assess typi[INVESTIGATOR_22588] -A2, immune cell 
levels, phenotype, pharmacokinetics, immunogenicity of the study drug 
ALT -801, and the serum levels of IFN -γ and TNF -α. Tumor samp les 
obtained from surgeries or biopsies performed prior to screening for the 
study will be collected to test the HLA -A*0201/p53 aa 264- [ADDRESS_436462] course of 
study treatment. Venous blood will be obtained at Time 0 (before the start of infusion), at 30 minutes (15 minutes after completion of infusion), and 1, [ADDRESS_436463] and second courses of study treatment. HLA -A2 typi[INVESTIGATOR_351102]. 
Monitoring Tests:  Urine samples for urinalysis, blood samples for standard chemistry, CBC, differential and coagulation will be obtained for tests required at screening for study entry eligibility evaluation or for tests required throughout the treatment and follow -up periods for patient safety monitoring. Blood 
samples for immunogenicity testing, which include assays for anti- ALT -[ADDRESS_436464] 
ALT -801 infusion day and at Week 9 from the initial dose of study 
treatment.  
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 07 
IND 100174  March 29, 2013  
 
 
Page 13 of 82 Anti -tumor  
Response  
Evaluation: The anti -tumor response will be evaluated for up to 22 weeks from the initial 
dose of study treatment: for non -responders: Week 9 and 13; for early 
responders: Week 9 and 18; for late responders: Week 9, 13 and 22. 
Objective Response will be ev aluated using the new international criteria 
proposed by [CONTACT_351121] 
(RECIST) 1.1. Baseline evaluations should be performed up to [ADDRESS_436465] of the treatment. However, 
cystoscopic evaluation may be used routinely in this population, in addition to radiologic testing. If surgeries or biopsies are performed after patients receive and respond to study treatment, tumor or tissue samples from thes e 
procedures will be collected to assess histopathological and immuno- cellular 
responses to study treatment. 
 Survival  
Assessment:  Progression- free survival and overall survival of all enrolled patients will be 
assessed at 6, 9, 12, 18, 24, 30 and 36 mont hs from the start of study 
treatment, or through the point designated as the end of the study follow up. 
Adverse Events:  All p
 atients will be monitored and evaluated for clinical toxicities during the 
treatment period and queried at each follow -up visit fo r Adverse Events 
(AEs). Patients may volunteer information concerning AEs. All adverse 
events will be graded by [CONTACT_351117] 4.0 (CTCAE v4.0), and logged in the patient Case Report Form. The study centers should report all SAEs and all events that trigger patient’s study treatment discontinuation to the sponsor via phone, fax or email (or a combination) up to 1 day after learning of the event. The sponsor will use the information to manage and coordina te the dose 
escalation, cohort expansion and patient enrollment. The sponsor will then inform all of the participating clinical sites of the current dose level and the number of patients to be enrolled at that level, or of any patient enrollment suspension via phone, fax or email within a day of its learning of the event. 
The study centers should report the other adverse events to the sponsor following the guidelines defined in the study protocol. All study drug related adverse events (AEs) that are both se rious and unexpected will be reported 
to the FDA in an expedited manner in accordance with 21 CFR §312.32. 
Statistical Plan:  For  each cohort, all AEs will be tabulated and examined and all safety and 
pharmacokinetic data will be evaluated. For estimation of duration of 
response, the Kaplan- Meier method will be used. P -values of < 0.05 (two-
sided) will be considered to indicate st atistical significance.  
 
CA-ALT -801-01-10 CONFIDENTIAL  Version#: 07 
IND 100174  March 29, 2013  
 
 
Page 52 of 82 8. STUDY CALENDAR, CLINICAL PROCEDURES & TE STS 
8.1 Study calendar  
TESTS & PROCEDURES  SCREEN1 INITIAL STUDY TREATM ENT  SCAN #1  SCAN #2  MAINTENANCE 
STUDY 
TREATMENT  SCAN #3  FOLLOW -UPS  
COURSE 1  COURSE 2  COURSE 3  
Month (late responders in parentheses)   1 2 3 4 3-5/(4-6) 
 
 
 
 
 5/(6) 6 
  
  9 12 18 24 30 36 
Week (late responders in parentheses)   1 2 3 4 5 6 7 8 9 13 10-17/(14-21) 18/ 
(22)  
Treatment Day   1 3 5 8 12  22 24 26 29 33  43 45 47 50 54     1 - 54 
 
 
  
Informed consent   X       
R 
e 
s 
t 
 
P 
e 
r 
i 
o 
d 
       
R 
e 
s 
t 
 
P 
e r 
i 
o 
d 
         
 
 
Follow 
Institution’s 
standard of care  
(SOC)  policy . If 
performed, follow 
the same schedule 
as the Initial 
study treatment.   
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
        
Medical history  X                          
Serum pregnancy test2 X                          
Complete physical exam16 X X     X     X     X X X        
Vital signs, weight, Height3 X X X X X X X X X X X X X X X X X X X        
Concurrent medication  X X X X X X X X X X X X X X X X X X X        
CBC with Differential, Blood Chemistry16 X X X X X X X X X X X X X X X X X X X        
Coagulation (PT/INR)4 X                          
Urinalysis  X X      X     X               
Cardiac functions5, 16 X X5 X X X X X5 X X X X X5 X X X X             
Pulmonary functions  X                          
Adverse event assessment6 X X X X  X X X X X X X X X X X X X X X        
Tumor assessment7 X                   X X X        
Survival Assessment8                      X X X X X X X 
HLA A2 Typi[INVESTIGATOR_007],  immune cell levels & 
phenotype11  X9 X9  X9    X9           
Not required           
HLA -A*0201/p53 tumor typi[INVESTIGATOR_007]    X                        
PK, IFNγ, TNFα11   X10                         
Immunogenicity tests11   X12               X                
Cisplatin    c115     c215     c315       Follow the same 
schedule as the Initial 
study treatment          
Gemcitabine   g1   g2  g3   g4  g5   g6            
Study drug (ALT -801)13    a1 a2 a3 a414   a5 a6 a7 a814   a9 a10 a11 a1214             
1 Obtain signed consent any time before performing screening evaluations.  Screening evaluations are performed < 14 days ; stress test, if requir ed, scan/x -ray < 28 days  prior to start of therapy.  If patient's condition is 
deteriorating, ECOG status and laboratory evaluations should be repeated within [ADDRESS_436466] is for women with childbearing potential only.  3Vital signs 
(especially blood pressure), clinical status and laboratory tests should be reviewed before start of therapy. Vital signs wil l be evaluated every 2 hours after study  treatment and before discharge (or at completion of dose 
monitoring) , and body weight before study treatment infusion on study treatment infusion day. 4PT/INR should be performed for any bleeding issues. 5Patients are closely monitored for hypotension, arrhythmia, angin a and 
myocardial infarction. At screening, patients who are ≥ [ADDRESS_436467] (stress thallium, stress MUGA or 
dobutamine echocardiogram) to determin e their eligibility for participation in the study. EKG will be performed for all patients at start of each study treatment course. At the start of 1st course, EKG is performed only 
when >[ADDRESS_436468] an on -going study drug -related SAE upon study completion or at discontinuation of the study will be contact[CONTACT_33981]/her designee every week until 
the event is resolved or determined to be irreversible. 7Tumor response and progression will be evaluated in this study using the new international criteria proposed by [CONTACT_39694] (1.1). 8Information about tumor 
assessment & other therapi[INVESTIGATOR_351103]   9Fresh blood samples for HLA A2 blood typi[INVESTIGATOR_007], immun e cell levels & phenotype testing will be collected before 
dosing. 10After Stage [ADDRESS_436469].  14This dose can be delayed to Day 15 of 
each course. 15Not required for patients enrolled to the non -cisplatin -containing arm of Expansion Group 2.  16Labs, physical exam, and EKG can be performed within 48 hours prior to start of each study treatment  course . 
 